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ABSTRACT 
INTRODUCTION:  Renal dysfunction is the common complication of 
HIV infection with a prevalence of 30 % in HIV patients. The spectrum of 
renal dysfunction is multifactorial ranging from exacerbation of chronic 
kidney disease to acute kidney injury. Kidney disease in the setting of HIV 
can pose a significant challenge to patients and clinicians by increasing the 
risk for AIDS-defining illness, hospitalization, and death.  
OBJECTIVES:  The prevalence of renal dysfunction among HIV-1 
infected outpatients starting ART in India is limited. Recent 
recommendations to include the Nephrotoxic drug Tenofovir in first-line 
ART regimens make clarification of this issue urgent 
METHODOLOGY :  We screened for renal dysfunction by measuring 
serum Creatinine, urea,  Microalbuminuria, USG – KUB, low CD4 counts 
and Opportunistic infections  in HIV-positive patients initiating ART at 
Coimbatore Medical College Hospital . We excluded patients with 
preexisting renal disease, hypertension, diabetes, pregnancy or Hepatitis B/ 
C virus co-infection.  eGFR were calculated by Cockcroft-Gault Equation, 
and eGFR was categorized accordingly based on National Kidney 
Foundation staging of Chronic Kidney disease : < 60 ml/min/1.73 m
2 
( 
Grade 3 or less) ; 60- 90 ml/min/1.73 m
2 
( Grade 2 ); <90 ml/min/1.73m
2 
( 
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grade 1 or normal ). e GFR calculated at the end of study was compared with 
Age, Gender, weight, CD4 counts , Urea , Creatinine and with different 
types of ART regimen used by the study population. 
RESULTS: Only 21 (21%) of 100 enrolled patients had normal eGFRs 
(Grade 0 or 1) above 90ml/min/1.73m2. Grade 2 renal dysfunction (eGFR 
between 60 and 90 ml/min/1.73m2) was present in 37 patients (37%), and 42 
patients (42%) had Grade 3 dysfunction 0r less (eGFR < 60 ml/min 1.73m2). 
Microalbuminuria  was detected in 47% of  patients. Mean eGFR was 69.28.  
70%  of  patients  fall  under  Tenofovir  based  regimen. Of which 64 % 
patients  falls in eGFR <90 ml/min and in particular  38% falls under eGFR 
< 60 ml/min which indicates moderate to severe renal dysfunction.   
Majority of them in WHO clinical stage I and low CD4 count <200 
associated with decline in eGFR. 
CONCLUSION : Renal dysfunction was highly prevalent in this population 
of HIV-positive outpatients initiating first ART in Coimbatore Medical 
College Hospital , Coimbatore. This highlights the critical and 
underappreciated need to monitor renal function in HIV-positive patients, 
particularly given the increasing use of tenofovir   in first-line ART. 
 Key words :  eGFR: estimated glomerular filtration rate, ART : 
Antiretroviral Therapy , Renal dysfunction. 
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INTRODUCTION 
 
                  Renal dysfunction is the common complication of HIV infection 
with a prevalence of 30% in HIV infected patients. The spectrum of kidney 
dysfunction  is  broad, ranging from exacerbation of common kidney 
diseases to acute and chronic conditions.
1
 The causes of renal dysfunction  
are  multifactorial  which  includes  HIV infection per se,  opportunistic 
infections ,  co-morbidities,  and  anti retroviral therapy . AIDS-related 
kidney disease, especially HIVAN ( HIV associated Nephropathy)  has 
become a relatively common cause of end-stage renal disease (ESRD)  
requiring renal replacement therapy and may be associated  with  
progression to AIDS and death. 
2 
                Elevated serum creatinine is the first evidence of renal 
dysfunction. Increase in Serum  creatinine  from baseline should prompt an 
evaluation. The  estimated  Glomerular filtration rate (eGFR) is a direct 
measure of kidney function and reduces before the onset of symptoms of 
Renal  failure. Severity of kidney disease directly correlates with decrease in 
GFR which can be calculated in the clinical setting using one of the three 
most commonly used equations: 
1. Cockcroft – Gault (CG) formula  
xix 
 
2. Modification of Diet in Renal Disease formula ( MDRD )  
3. Chronic Kidney Disease Epidemiology Consortium formula (CKD- 
          EPI) 
                        Any of these equations may be used to follow trends in 
creatinine ,as part of determining GFR. Cockcroft-Gault equation is the 
most commonly used which estimates GFR using serum creatinine 
measurements and anthropometric variables.  
 
                     The incidence and spectrum of kidney diseases in HIV have 
been dramatically altered by ART .The risk for ESRD has been reduced and 
survival on dialysis is expected to improve with newer antiretroviral drug 
therapies . 
 
                      Patients with HIVAN who are on effective ART have a slower 
decrease in GFR  and less incidents of fulminant renal failure .HAART is 
responsible for at least a 30% reduction in new ESRD cases from HIVAN
3
 
.However, initiation of ART may not have a beneficial effect on the natural 
history of other forms of CKD, such as IgA nephropathy and diabetes, which 
could be mistaken for HIVAN when a biopsy is not obtained. 
 
xx 
 
                     The present study was undertaken with an aim to investigate 
the factors associated with decline in estimated GFR using CG formula  
among the patients initiated on Highly Active AntiRetroviral Therapy 
(HAART) and its correlation with renal dysfunction and progression to  end 
stage renal failure. 
                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxi 
 
OBJECTIVES 
 
1. To study the Renal Changes  in Adult HIV Patients following  first line 
HAART initiation using  estimated Glomerular filtration rate ( eGFR ). 
2. To study the Renal changes and decline in  eGFR with  respect to the 
different     HAART regimens  after the HAART initiation by using 
Cockcroft – Gault formula. 
3. To consider that close monitoring of  Renal function is important ,as the 
current use of specific antiretrovirals may result in an increased risk of 
eGFR decline in HIV – 1 infected patients on HAART. 
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                                   REVIEW OF LITERATURE 
 
HISTORY OF THE  HIV /AIDS 
                         Acquired  Immunodeficiency Syndrome (AIDS) is a global 
epidemic caused by Human Immunodeficiency Virus (HIV) currently 
sweeping throughout the world. 
1981 – New syndrome AIDS was first recognized in the intial outbreak with 
high mortalility, when US , CDC reported high number of cases of  rare 
cancer ,  Kaposi sarcoma and rare  Pneumocystitis  jiroveci pneumoni 
among healthy homosexual  men 
1983 – HIV was isolated from a patient with lymphadenopathy by 
            Dr.Luc  Montagnier 
1985 – Cases of AIDS reported in 55 countries 
           FDA approved ELISA as sensitive diagnostic test 
1987 – WHO estimated  upto 1,50,000 cases exist worldwide 
            Azidothymidine became first anti – HIV drug approved by FDA 
1988 – World AIDS day was first declared by WHO on December 1 
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1990 – WHO estimates nearly 9 million people with HIV and 1 million with 
AIDS 
1991 -  First protease inhibitor , Saquinavir approved by FDA 
2000 – UNAIDS estimates 53 million people worldwide have contracted 
HIV/AIDS and 17 million died so far 
2006 – June 5 marks a quarterly century since first AIDS case reported4. 
 
ORIGIN OF HIV/AIDS 
                      In early 1980’s one hypothesis was put forward that , there 
exits a close genetic relationship between humans and primates and the HIV 
virus was transmitted to humans from  primates .Non human primates 
(monkeys and apes) are only an asymptomatic carrier of HIV like virus 
called SIVs ( Simian Immunodeficiency Virus) and no disease manifests in 
these primates. 
            Genetic sequences of HIV and SIV were compared.  .In 1989, 
scientist demonstrated that RNA sequence of SIV from both captive and 
wild Sooty mangabeys were similar to HIV – 25.This supports the 
xxiv 
 
overlapping geographical distribution and idea of cross species transmission 
in West Africa. The origin of this HIV -1 virus was unclear for many years. 
The natural habitat of Chimpanzee and Gorilla coincides with geography of 
HIV -1 epidemics in central Africa  and their  SIV and human HIV -1 
sequences were similar
6
. Most likely the virus was acquired through killing 
and butchering chimps and monkeys in the “bushmeat” trade. 
           Two types of HIV can infect humans  HIV- 1 and HIV- 2.HIV -1 is 
most common and more widespread throughout the world . HIV – 1 has 
several  subtypes ( M,N,O,P) and has different geographic distributions. 
AIDS pandemic s primarily caused by HIV -1 M group. HIV 2 mostly 
occurs in West Africa. It has subtypes from A through G. 
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EPIDEOMOLOGY 
                       Globally, an estimated 35.3 (32.2–38.8) million people were 
living with HIV in 2012. An increase from previous years as more people 
are receiving the life-saving antiretroviral therapy.  
                There were 2.3 (1.9–2.7) million new HIV infections globally, 
showing a 33% decline in the number of new infections from 3.4 (3.1–3.7) 
million in 2001. At the same time the number of AIDS deaths is also 
declining with 1.6 (1.4–1.9) million AIDS deaths in 2012, down from 2.3 
(2.1–2.6) million in 2005 7.  Graph 1 . 
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STRUCTURE OF HIV VIRUS 
 
                The integrated form of HIV – 1 ,also known as provirus is 
approximately 9.8 kilobases in length .The genes are located in the central 
region of proviral DNA and encodes atleast 9 proteins. The median 
incubation period is ten years 
8.
 Figure 1 . 
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                                  Figure 2 :  HIV LIFE CYCLE 
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1993 Revised Classification System for HIV 
Infection 
 
The revised CDC classification system for HIV-infected adolescents and 
adults categorizes persons on the basis of clinical conditions associated with 
HIV infection and CD4+ T- lymphocyte counts. The system is based on 
three ranges of CD4+ T- lymphocyte counts and three clinical categories and 
is represented by a matrix of nine mutually exclusive categories 
CD4+ T-Lymphocyte Categories  
The three CD4+ T-lymphocyte categories are defined as follows:  
Category 1: greater than or equal to 500 cells/mL  
 Category 2: 200-499 cells/uL  
 Category 3: less than 200 cells/uL  
 
These categories correspond to CD4+ T-lymphocyte counts per microliter of 
blood and guide clinical and therapeutic actions in the management of HIV-
infected adolescents and adults 
9. 
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CLINICAL CATEGORIES 
Category A 
         Documented HIV infection in adults more than 13 years with persistent 
generalized lymphadenopathy , asymptomatic HIV infection, acute HIV 
infection with accompanying illness
10
.Conditions in B and C have not 
occurred. 
Category B 
        Symptomatic conditions in an HIV-infected adolescent or adult that are 
not included among conditions listed in clinical Category C and that meet at 
least one of the following criteria: a) the conditions are attributed to HIV 
infection or are indicative of a defect in cell-mediated immunity; or b) the 
conditions are considered by physicians  to  have  a clinical course or to 
require management that is complicated by HIV infection. 
Category C 
       Clinical conditions listed in the AIDS surveillance case definition. For 
classification purposes, once a Category C condition has occurred, the 
person will remain in Category C 
 
xxx 
 
Table 1 : 1993 Revised Classification System 
 
CD4+ T cell 
Categories 
A 
 
Asymtomatic, 
Acute HIV or 
PGL 
B 
 
Symptomatic 
Not A or C 
C 
 
AIDS- indicator 
Conditions 
 
>500/micL 
 
A1 
B1 C1 
 
200-499/micL 
 
A2 
 
B2 
 
C2 
 
< 200/micL 
 
A3 
 
B3 
 
C3 
 
 A3 , B3 ,C1 ,C2 ,C3  category persons have AIDS according  to 1993 
surveillance case definition 
 
 
 
CLINICAL ASSESSMENT BEFORE  STARTING  ART  
 
  After confirmation of HIV infection by serological or virological 
evidence , Clinical staging is used . Clinical staging in established HIV 
infection is given in Table 2 . It is useful for assessment at baseline  before  
starting ART and to guide in making decision about starting ART and other 
prophylaxsis 
11,12. 
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Table 2 : WHO CLINICAL STAGING OF ESTABLISHED HIV   
INFECTION 
[20] 
  
 
 
 
CLINICICAL ASSESSMENT OF PEOPLE RECEIVING ART:    
    
              Clinical status can be effectively reversed by different ART 
regimens with good viral suppression and immunological recovery  
.
[13,14].
.People on  ART  for more than 24 weeks can have new or recurrent 
clinical staging events,which help in further decision making  .In first 24 
weeks its due to immune reconstitution. After 24 weeks its due to immune 
suppression 
[15,16.] 
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 IMMUNOLOGICAL ASSESSEMENT BY CD4 COUNTS 
 
                       The prime target cell for  HIV virus is CD4+ T lymphocyte, as 
virus has high affinity for CD4 surface marker.
[17]
.  Normal absolute 
lymphocyte count in adults, ranges from 500 to 1500 cells/mm3. As HIV 
disease advances , CD4 count progressively decreases and the risk and 
severity of opportunistic infection increases. 
                        In response to effective combination ART ,CD4 counts 
increases though  it  takes  many  months 
[18]
. Adults  started on ART with 
CD4 counts  >200-350 mm3 have better virological outcomes when 
compared to CD4 count <50mm3
[13,14,19]
.  
                        Commencing ART can be delayed if there is mild 
immunodeficiency ( CD4 count >350mm3 in adults) or the patient is 
asymptomatic. So, CD4 testing is a useful guide in starting first line ART , 
initiating  cotrimoxazole  prophylaxsis  , identifying treatment failure and to 
assess and monitor response to ART. 
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Table 3 : WHO IMMUNOLOGICAL STAGING OF ESTABLISHED 
HIV INFECTION 
[20] 
 
 
 
Table 4 :  WHO CLINICAL STAGING IN ADULT HIV/AIDS  WITH 
ESTABLISHED  HIV INFECTION 
[20]
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COURSE  OF  UNTREATED  HIV  DISEASE:  
Figure 3 : 
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VIRAL  TRANSMISSION 
                     HIV infects initially with tansmission of virus. The mean 
incubation period is 5 days .Within that people become infectious to others, 
even before the onset of any symptoms and life long they will remain 
infectious to others. 
PRIMARY HIV INFECTION 
                      The virus initially localize to regional lymph nodes, after 
transmission  and  then   disseminates to GIT ,genital tract and other 
lymphoid organs.
[21] 
So in the first few weeks there is  one million copies 
/mL of plasma viral load. [21] . In the following next few weeks ,plasma 
viremia decreases with effective cellular immune mechanism of host. 
[22}  
                                      
Up to 70% of  newly infected people experience “flu-like” 
symptoms (fevers, chills, night sweats, rashes).  Within 14 days, Acute 
primary illness resolves spontaneously 
[23] 
 
WINDOW  PERIOD AND  SEROCONVERSION 
                 The  window  period  begins with initial infection and continues 
until the virus can be detected by an HIV antibody test. Seroconversion  is 
xxxvii 
 
the is the term for the point at which HIV antibodies are detectable and the 
window period ends. 
[23] 
 See below, Graph 2  
 
 
 
ASYMTOMATIC HIV  INFECTION ( CLINICAL LATENCY 
PERIOD ) 
 Following  seroconversion  patient enters a prolonged asymptomatic period. 
The person may look and feel healthy , but still virological and  
immunological  progression  occurs, which can go for longer than 10 years 
[23,24]
 During this time the only indication of clinical  HIV infection occurs  
through testing or the presence of swollen lymph glands . 
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SYMTOMATIC HIV INFECTION  
Symptomatic HIV disease is due to Progressive and sub-clinical, immune  
deterioration  of the host defenses . It can take 5 to 7 years for mild 
symptoms to occur. Some common symptoms,which are non is specific to 
HIV disease are
[23]
: 
 Persistent low grade fever 
 Persistent diarrhea 
 Significant weight loss 
 Chronic vaginal or oral thrush 
 Recurring herpes blisters 
LATE STAGE AIDS 
                            Late stage AIDS disease is diagnosed by HIV specific 
blood test and patients general condition.  In late stages, the T-cell count 
drops down to 200 or less, and opportunistic infections develop. These are 
infections and illnesses that the normal immune system can suppress or 
present.  There is an increase in Plasma viral load few years before  the 
development of AIDS 
[25,26] 
                             Death occurs from extensive involvement of vital organs , 
from effects of circulatory toxins, circulatory and haematopoietic failure . 
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RENAL DISEASE AND HIV 
 
HISTORICAL PERSPECTIVE 
                   In 1984, Roa  and others diagnosed a focal and segmental 
glomerulosclerosis  in 10 out of 92 black patients diagnosed to have AIDS at 
King Country Medical center,New York city, and there was a rapid 
progression to severe uremia in all those patients 
[27]
. This report supported  
HIV as the causative agent for AIDS. 
                     In certain geographical areas existence of AIDS nephropathy , 
was not accepted due to low incidence . Since then ,the prevalence of 
HIVAN has increased over  past  25 years , attained peak in mid 1990’s and 
then  remained stable  after introduction of ART with  an initial decline since 
1996
[28} 
. 
 
SPECTRUM AND EPIDEOMOLOGY  
                   Kidneys  have been reported to be commonly involved in HIV 
infection with a prevalence of 30%. It is a proven reservoir of  HIV 
infection. The spectrum  of  kidney  involvement is  broad ranging  from  
exacerbation of common kidney diseases , fluid and electrolyte imbalances 
to HIVAN which  progress rapidly to renal  failure 
[1]
.    
xl 
 
                 Acute renal failure  is  more  prevalent  in HIV positive  
individuals. The  common   causes  include  prerenal  azotemia following   
poor fluid  intake, diarrhoea  and  hypovolemia.   ATN   can be due  effects 
of  Nephrotoxic drugs  and sepsis 
[33]
.Volume depletion in HIV patients is an 
important predisposing  factor for  Acute renal failure.     
                   Prevalence of HIVAN is from 3% to 12% found in autopsy 
series,as data for HIVAN  not exist in AIDS case definition 
[30]
. However,  
because of the lack  of definitive diagnosis of HIVAN by kidney biopsy, 
most studies provide estimates of renal involvement (eGFR)  in HIV-1–
infected individuals rather than true prevalence of HIVAN 
[29] 
. It causes 
progressive renal failure with both glomerular  and  tubulointerstitial  
components. 
                     Chronic renal failure (CKD) can occur in HIV  patients .  The 
risk factors  are same  as in   HIV  negative  persons. The evaluation  should  
begin with ruling out the secondary causes of glomerular disease which 
manifest as proteinuria and elevated urea and creatinine like Diabetes, 
Hypertension, Malignancy, HCV, HBV or Syphilis.  
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                    Urine analysis  is important as it is very sensitive  indicator of 
renal dysfunction even with  normal GFR, whereas  GFR needs to drop to 
50% of normal  in order to reflect  any  abnormality in  renal functions. 
                         HIV associated renal diseases are due to HIV infection per se 
or due to certain antiretroviral drugs  used or  due to pharmocological drugs  
used in the treatment and prophylaxis of associated opportunistic  infections.      
                       Atleast  transient  alternations  in renal  function  can  occur in 
all stages of diseases  in  individuals  with HIV infection. Mortality  due  to 
renal disease in HIV  is correlated  with  complications  of  infections  rather  
than  due to presence of  renal  disease  or  need for dialysis  per se 
[34,35] 
                      In HIV positive patients, ART has modified the manifestations 
of  renal diseases , especially  the incidence of HIVAN , risk of ESRD and 
the need for hem dialysis has been reduced in HAART era 
[31]
. Patients with 
HIVAN who are on ART will  have atleast 30% reduction in fulminant renal 
failure 
[32] 
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GLOMERULAR  FILTRATION  RATE  
                         The central function of the kidney is to filter the metabolic 
waste products  from  the blood  and to eliminate them from the body. eGFR  
is  widely used and is the best overall measure of renal function.  
                       GFR  indicates  amount  of  filtrate passing  into the 
Bowmann  space from the glomerular capillaries   per unit of time,  and it is 
calculated  by measuring the clearance of  specific marker substance. GFR 
varies with sex and age, but  is 120 - 130 ml/min/ 1.73 m2 surface area  
approximately in adults 
[38]. 
                                 
A substance or molecule which is an ideal marker for 
measuring the Clearance(CL) should not be  protein bound, is freely filtered 
at the glomerulus , neither  reabsorbed, secreted , metabolise   or synthesized  
by  the  renal tubules  and  excreted   only   by  the kidney. So far ,such  an 
ideal biomarker  is not found  . 
                        GFR can be measured as a renal clearance of various 
exogenous markers, which  are of  impractical in routine use. They are 
Inulin, Non-radiolabelled  contrast  media ( iothalamate/iohexol) , 
Radiolabelled contrast media ( 51Cr-EDTA),  99mTc DPTA,  I 131 
Hippuran.  
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                    Endogenous  markers  include  Urea, Creatinine and Cystatin C. 
The  Commonly used marker to measure GFR in clinical laboratory is serum 
Creatinine , however  it  has multiple limitations.
[37]  
Rather than depending 
on GFR alone,  Plasma  creatinine  is  also influenced by factors like 
muscular mass, diet, age and gender.  
                             The new  endogenous  biomarkers are  beta2-microgobulin and 
Cystatin C. Serum Cystatin C is a potential alternative to creatinine for 
estimating  GFR. In view of  prognosis  , it’s a better marker  in chronic  
kidney  disease than plasma creatinine.
[36]
 
 
ESTIMATING  GLOMERULAR  FILTRATION  RATE 
                   For  GFR estimation  from plasma creatinine concentration,  
various formulas which incorporate variables like age, gender, height and 
weight can be used. Here are some commonly used formulas : 
1. COCKCROFT-GAULT (CG) equation :  
It was derived in 1976 from a cohort of  290 hospital patients.
[39].
 It is based  
on patient age ,gender , weight and  serum  creatinine.  
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   CG equation: 
 
             (140-age in years) x  Weight in Kg 
           e GFR (ml/min)  =    ---------------------------------------------------- 
                                              (Weight/72)  x Serum creatinine  (mg/dL) 
  
           ( In female , multiply the result by 0.85) 
                       The above formula is adjusted for black patients, also it may     
 overestimate creatinine  clearance  in  patients who are malnourished or 
who have  edema. This  equation  was  validated  in  200  hospitals  with  a 
broad  range of  creatinine  clearance  values 
[39]
. 
 
2. THE MODIFICATION OF DIET IN RENAL DISEASE 
     (MDRD)  Formula : 
                  It was derived in 1999 from a cohort  of 1628 cases  with CKD in 
the MDRD study
[40]
. It  Estimates GFR based on age, sex , race , and serum 
creatinine.  
MDRD Formula: 
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                The  MDRD  formula was validated in a sample  of  patients in 
MDRD  study, who also  had CKD  and  GFR  values  between  20-60 
ml/min/1.73 m
2. 
CG equation measures creatinine clearance(CL) , while 
MDRD    measure   GFR  directly. 
3. THE CHRONIC KIDNEY DISEASE EPIDEOMOLOGY 
COLLOBORATION (CKD-EPI)  Formula : 
                   It  was  derived  in 2009  from  a  collaboration of   clinical  
studies  and  data  from   the   Nutrition  Examination  Survey and National 
health  in America between 1999 and 2006 
[41]
. It  is  based  on  age,  race 
and  serum creatinine.  
CKD-EPI  Formula  : 
 
 
                      The CKD-EPI  formula  was found to be more specific than 
the MDRD study formula especially at  high  glomerular  filtration  rates in 
the validation  sample. 
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                        Cockgroft  and  Gault (CG) equation is the best validated and 
widely employed equation. 
 
 
ACUTE KIDNEY INJURY 
Definition 
  The AIDS  Clinical Trial  group  has  defined  Acute Kidney Injury (AKI)  
in HIV-seropositive  patients  as  a  creatinine  level  more   than 1.5 mg/dl 
or  a 1.3 fold  raise  from  baseline  that  can  be  reversible  within  3 months 
.    
            The basic   causes  and mechanisms of ARF  is similar to as  in HIV  
negative  patients. But  some  causes of AKI  are specific to HIV infection. . 
It may be  classified  as  prerenal,  intrinsic  and  post renal causes. 
 
         In  hospitalized  patient , the  most  common  causes  are pre renal 
causes  in  38%  of  patients   due to volume depletion  and Acute Tubular  
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Necrosis (ATN ) in 58%  of  patients , contributing  52%  in overall ,due to 
 infection,  septicemia, ischemia,  bleeding,  hypoalbuminaemia, or  
nephrotoxins
[42]
.   Interstitial  nephritis  ,  obstructive  nephropathy and 
interstitial nephritis are very rare causes. 
                 There is  an increasing  incidence of HIV – associated thrombotic 
microangiopathies and rhabdomyolysis, the latter due to the use of statins 
with antiretroviral drugs.  
                 
                 Post-renal AKI ,though rare , can occur due to malignancy , 
lymph nodes, retroperitoneal fibrosis, or   crystalluria due to indinavir, 
foscarnet,   sulphadiazine or acyclovir. More  recently,   atazanavir   has  
been associated  with  nephrolithiasis,  but  unlike  indinavir
[43]
  this  
protease  inhibitor  has  not  been associated  with obstructive  AKI  or  with 
AIN.  
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Table 5: Causes of Acute Kidney Injury in HIV- infected 
individuals
[43] 
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Table 6 : RISK factors for HIV induced AKI 
[43] 
 
AKI and Oppurtunistic Infections (OI’s) 
 In Pre-HAART era, AKI incidence and mortality was due to septicemia and 
opportunistic infections.In  ART era, the incidence due to opportunistic 
infections are rare, which are : 
1. Parenchymal fungal infections 
2. Granulomatous nephritis with Mycobacterium 
3. Interstitial nephritis due to Epstein Barr Virus, Polyoma virus and 
Cytomegalovirus. 
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PNEUMOCYSTITIS PNEUMONIA 
       AKI  in pnemocystitis is due to clumps of organisms obstructing 
tubular and glomerular capillaries, which leads to form renal calcification on 
Computerised Tomogarphy  
[44]
. 
         Cotrimoxazole  in  high dose is a nephrotoxic agent and  it is use 
should be  used  carefully.  In  patients with renal  impairment  , the 
treatment is as follows given in Table  
Table 7 : PCP treatment in renal insufficiency
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CMV, HSV AND VZV infection 
Table 8 : Treatment of CMV, HSV, VZV infection in renal insufficiency
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TOXOPLASMA  ENCEPHALITIS 
Table 9 : Treatment of  cerebral  toxoplasmosis  in  renal  insufficiency 
 
 
In the post – HAART era 
  After the introduction of ART , cases of Acute Interstitial Nephritis 
(AIN) due  to  IRIS ( Immune Reconstitution Inflammatory Syndrome ) 
have  been reported. IRIS is a systemic inflammatory response to infections 
or to non-infectious diseases that can manifest as the immune system is 
restored after the initiation of ART.
[46] 
            It should be considered after excluding other causes of ARF. In these 
cases, renal function may drastically improve after initiation of steroid 
therapy. In one recent study reported from London , IRIS contributed to 6 
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out of 144 patients within 90 days of initiation of ART, mostly due to 
exacerbation of infections like Mycobacterium avium, Cryptococcosus, 
Pneumocystitis, hepatitis B.
[45] 
 
CHRONIC RENAL FAILURE 
DEFINITION 
                 
 National Kidney Foundation defines Chronic Kidney Disease by 
the presence of protenuria and estimated GFR < 60 mL/min/1.73m
2
 of  
atleast 3 months duration. HIVMA –IDSA guidelines also recommends this 
definition.
 
It graded by calculating the estimated glomerular filtration rate  
using  modified Cockcroft-Gault equation or by use of the MDRD 
equation.
[48] 
 
  The  Table 10  gives guidelines for screening  HIV patient for CKD. 
This  screening  guidelines will helpful to follow up the patients who are 
started on ART with nephrotoxic potential, in particular Tenofovir. These 
patients may benefit  from more frequent assessments of their GFR,  serum 
phosphate levels, and  urine albumin  to monitor for early signs of 
nephrotoxicity.
[47]  
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 Table 10:  NKF and IDSA guidelines for screening CKD 
 
CKD risk factors: African American,  CD4
+
 cell count < 200 cells/mm
3
,  HIV-1 RNA >14,000 copies/ml , 
diabetes, hypertension, dyslipidemia, cocaine/cigarette use, hepatitis co-infection 
. 
Based on National Kidney Foundation(NKF) and  Kidney Disease Outcome 
Quality Initiative (K/DOQI) Clinical Practice Guideliness ,CKD is classified 
into five stages, based on estimated GFR and irrespective of diagnosis given 
in Table 11, 
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 STAGES OF CHRONIC KIDNEY DISEASE AND CLINICAL ACTION PLANS
 
Even in post HAART era, there is increased mortality and progression to 
AIDS in Chronic kidney disease patients.
[49].
 Adverse  effects with protease 
inhibitors (PIs) are more common in patients with CKD.
[50]
 
There  are  various  spectrum of  hisopathology in HIV patients with CKD.  
Of the various causes of , the three variants are common,which include:  
 Focal Segmental Glomerular sclerosis  
 Immune complex renal disease  
 Microangiopathic renal disease  
 
lvi 
 
HIVAN  
          HIV Associated Nephropathy ( HIVAN ) is the frequently  
recognized and most prevalent causes of CKD in HIV infected individuals. 
It is characteristically most common in African  population  when compared 
to   Asian population and can occur in any CD4 count 
[51]
.  
 In virologically suppressed patients,  HIVAN is extremely rare because here 
viral replication is directly related to renal injury.  In untreated patients,  
HIV- associated nephropathy is typically characterized by abrupt decrease in 
renal function , asscociated with  proteinuria  of high grade, no pedal edema 
and  large  echogenic kidneys on ultrasound .  
         ART is found to preserve renal function and prolong survival in 
HIVAN. Therefore , even at the earliest sign of renal failure , ART  initiation 
should be encouraged started in all individuals. 
Clinical features  
         The onset is usually insidious. The patient may be  asymptomatic and 
unaware of the renal dysfunction until the disease is advanced and only few 
renal function remains. It is generally a late manifestation years after HIV 
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infection. Very Rarely, HIVAN can present during acute HIV viral 
syndrome in primary infection 
Late stages of HIVAN presents as nephrotic syndrome with : 
 Nephrotic range proteinuria ( > 3.5 gm/ 24 hours) 
 Absence of Hypertension 
 Peripheral edema may be present at times 
 Less hyperlipidemia 
 Hypoalbuminemia 
 Rapid decline in GFR and progress to ESRD  with  
 Serum creatinine > 2mg/dL 
 Large echogenic kidneys despite renal failure on ultrasound 
 Renal biopsy shows findings of  Focal Segmental Glomerulosclerosis 
( FSGS)  
         In  Urinalysis ,there will be sediments  with varying numbers of red 
blood cells , proteinaceous casts  and  epithelial cells of tubular origin. 25 % 
can have pyuria . Proteinuria may show a wide variation in values in patients 
with HIVAN.
[52]
 .In one review  of South African case reports , the mean 
value of proteinuria in biopsy specimens  of HIVAN  patients was 11.8 
gm/d. , but the actual the range observed in the study was 0.7 to 40 gm/d.
[52] 
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Histopathology 
         Definite diagniosis of HIVAN requires renal biopsy and it should be 
done  if the clinical criteria meets without any contraindication. The decision 
for biopsy is controversial. Biopsy diagnosis is predictive only in 55- 60% of 
patients with HIVAN, even with classical clinical features. 
         To differrentiate HIVAN from  other common forms of renal disease. 
(eg., immunoglobulin-A nephropathy, immune complex glomerulonephritis) 
,there is a practice of doing renal biopsy in all HIV positive patients , whose 
daily protein excretion is more than 1 g /day 
[53]. 
                  
In light microscopy ,the most common histological picture is  
Collapsing  glomerulosclerosis and severe tubulointerstitial injury
[54]
 .The  
capillary tuft of glomerulus  is collapsed and may be sclerosed  globally or 
segmentally . The unique feature is severe retraction of   glomerular 
capillaries with podocyte swelling and hyperplasia which obliterates 
Bownmann’s space as “ pseudocresents” [55]  shown in Fig 4 . 
        Tubulointerstitial disease is also a predominant feature with microcyst 
formation ,cylindrically dilated tubules containing large proteinaceous casts. 
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Fig 4:Trichrome  staining  in  light  microscopy   shows  a collapse of the 
glomerular tuft  with sclerosis (bluish staining) of  segment of  
glomerulus and interstitium .  Dilated renal tubules are filled  with  
proteinaceous material. 
 
 
Fig 5 : Light microscopy picture showing microscopic dilatation of renal 
tubules enclosed with proteinaceous material. 
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              In   Immunofluorescent  microscopy , staining  for  immunoglobulin 
G ,M , C3 in epithelial cells  and A in  sclerotic areas.   In pododcytes, there 
is   increase of proliferation markers of podocytes and  decrease  of 
differentiation  markers 
[56]
. 
                  Electron microscopy shows  basement membrane wrinkling , 
proliferation of  epithelial cell  and  effacements  of  foot  process.  In   
endothelial  cells of glomerulus , presence  of  tubuloreticular structures  is  
highly  predictive  of  HIVAN. 
 
 
 
Fig 6 : Electron microscopy showing a endothelial cell swelling in 
glomerulus with effacement of podocytes (black arrow) and 
tubulointerstitial inclusions ( red arrow). 
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            In HIVAN , though collaping glomerulopathy is the most common 
presenting lesion ,but other glomerular lesions like IgA nephropathy, 
cryoglobulimemia, amyloidosis , and lupus like immune glomerulopathy. 
             HIVAN causes rapid progression to renal failure and in turn to 
ESRD in pre antiretroviral era. HAART has made a dramatic change  in  the 
natural  course of  disease  and  has  reported  stabilization and improvement 
in disease including histological changes ,thus emphasis the importance of 
early prompt evaluation ,diagnosis  and treatment
[27] . 
             Current guidance is for initiation of HAART in all patients where 
HIVAN is confirmed irrespective of CD4 counts
[57]
. 
 
CAUSES OF CKD OTHER THAN HIVAN 
                
            Among non- HIVAN causes of glomerulopathies the most common 
are membranoproliferative glomerulonephritis, membranous nephropathy , 
HIV immune  complex  disease  and  diabetic nephropathy
[49].
 These  disease  
attribute to CKD  most commonly in  non-black people,  Hepatitis B  
coinfected ,and in people  normal Blood  Pressure and  with  high  CD4 
counts
[49]. 
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      Based on biopsy findings, there  is  wide  spectrum  of 
glomerulonephritis , which is categorized as follows: 
1.HIV – FSGS ( ‘classic disease ‘) 
2.HIVICK :  group includes  Hepatitis B and Hepatitis  C co-infection 
 The  patterns in  this group are: 
 Mesangial proliferative 
 Membranoproliferative (type I and III ) ,lupus like nephritis 
 Exudative – cresentric and  proliferative Ig A 
 Membranous 
3.Various other glomerulopathies : This is big group with varied etiologies. 
 Immunoactoid  
 Minimal change 
 Amyloidosis 
 Nephrosclerosis and Comorbid disease – Diabetes, Hypertensive 
  4.HIV- TTP/HUS 
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Table 12 : IMMUNE COMPLEX KIDNEY DISEASE IN HIV
[57] 
HISTOLOGICAL 
PATTERN 
IMPORTANT ECONDARY 
CAUSES/ASSOCITIONS IN 
HIV 
HIV immune complex 
kidney disease ( HIVICK) 
 
Membranous GN Syphillis , HBV , Neoplasia 
IgA Nephropathy Chronic liver disease 
Post infectious GN Streptoccocal ,Staphylococcus 
infection. 
Bacterial, fungal, viral or 
parasitic disease 
Mesangiocapillary GN HCV, HBV, Chronic infection 
(eg.SBE), SLE, Drugs 
Immunoactoid / Fibrillary 
GN 
HCV , Neoplasia 
Lupus like Nephritis  SLE 
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There  are variety of histological entities in HIV immune complex disease 
which is shown in Table 12 . HIVICK the renal infiltrate is B lymphocytes 
,whereas in HIVAN it is T lymphocytes and macrophages. 
         It is more prevalent in Non blacks 
[58]
. Clinical spectrum is similar  to 
GN in non- HIV individuals ranging from asymptomatic proteinuria to 
ESRD 
[57].
The renal lesions may be due to direct result of HIV infection or 
due to associated coinfection ( Hepatitis B or C ).  
         There are common etiological factors for different forms of HIVICK   
like characteristic cytokine expression, inflammatory infiltrates, renal 
scarring ,genetic factors and deposition of circulating immune 
complexes.(CIC ‘s).  CIC ‘s are formed in all stages of HIV infection due to 
Immunoglobulins (IgG, IgM, IgA) which  binds to circulating HIV antigen 
(p 24, 8p G1 gp 120)
[59]
 . 
         The most common ICD in HIV is Membranoproliferative 
glomerulonephritis. Other  lesions  has  also been  described  such  as  
membranous nephropathy , IgA  nephropathy, Fibrillary  GN. 
          In  one  postmortem study ,there  was report of   IgA nephropathy  
occur  in  8 % of  the individuals. It can  present  as  hematuria, protenuria 
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and renal  impairment  of  mild  degree  and  is  less  in  severity  than  other  
variants of  HIVAN  and  HIVICK. 
          Classical  features  of  Lupus  like  nephropathy is proteinuria 
,hematuria, and  renal failure  which  rapidly  progress  to ESRD. It is more 
common   in   African  decent  males  and  can   usually   negative  
seropositivity  for  lupus.  
          Biopsy  picture  can have focal or diffuse proliferative changes, 
tubulointerstitial   scarring ,   cresent  formation  and  membranous 
nephropathy.  
Fig 7: ELECTRON  MICROSCOPIC  FEATURES IN IMMUNOLOGIC 
GLOMERULAR DISORDERS 
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          There  has  been  reported  good   response  for  HIVICK  with 
HAART  therapy, glucocorticoids  and  ACE  inhibitors. 
HIV ASSOCIATED THROMBOTIC MICROANGIOPATHIES  
            In 1984, its  renal  involvement  was  first  described  in AIDS patient 
by Boccia et al. It occurs in two classical forms : TTP ( Thrombotic 
thrombocytopenic purpura) and HUS ( Hemolytic Uremia Syndrome). Renal 
impairment and microangiopathic hemolytic anemia predominates in HUS 
whereas TTP is a  pentad  of  fever, neurological changes, microangiopathic 
anemia, thrombocytopenia and renal dysfunction. 
            HIV  associated  TTP/HUS  is  more  common  in  young  age  group 
with  80%  male  predominance.The  clinical  features  are  similar  to 
idiopathic form,  with  worse  prognosis  and  a  mortality  of  66  to 100%. 
Proteinurias  will be  in  the  nephritic   range  only  and  this  helps to  
differentiate  it  from  HIVAN and other  immune  related  nephropathies. 
           Renal  histology  similar  in   both  forms  which  shows platelet and 
fibrin thrombi are deposited in glomerular capillaries, renal arterioles, and 
interlobular  arteries. Arterial  intimal  and  endothelial  cell oedema, 
mesnagiolysis, microcystic  lesions in tubules , fibrinoid  necrosis  and 
‘onion skin’ lesions  are  the  features  as  in  HIV negative  individuals.. 
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           Immunofluorescence  shows  fibrinogen  and  fibrin  in  arterioles  
and  fibrinogen,  C1Q,  C3,  C4,  IgA, IgM light chains deposits in 
glomerulus.  Electron  microscopy  shows  tubuloreticular inclusions  in 
endothelial cells of blood  vessels . 
HAART  INDUCED  NEPHROTOXICITY 
           HAART  Nephrotoxicity  is  a  diagnosis  of  exclusion , since  there  
is a vast  etiological  spectrum  for  HIV  induced  renal failure.  
Nephrotoxicity  due  to  ART  accounts  for  14%  of  late onset AKI , 
frequently occurs in first 3 months of starting ART and significant mortality 
occurs within the first year.  HAART can cause various toxic effects to 
kidney, which can manifest as renal stones, tubular necrosis, ARF or  
CKD
[60]. 
           DART trial was conducted in 3316 symptomatic ART naïve adults  
with CD4 counts of < 200cells/mm3 . Post initiation with HAART showed 
an incidence of severe renal dysfunction ( GFR <30 mL/mim)  occurred  in 
2.7 % patients who were started  with tenofovir –lamivudine plus zidovudine  
(74%), abacavir (9%) or  nevirapine (16%) and  the mortality  was usually 
attributed  to associated  comorbid  diseases. Not  assessing  the  function of  
renal tubules  is  the  important  limitation  of  this  study. 
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             Though the overall  renal dysfunction have low incidence                 
( 0.3 to 2 % )
[63]
, tenofovir is most commonly associated with Fanconi’s 
anemia. Nucleoside analogs have a favorable renal safety profile, with only 
rare reports of direct toxicity to the renal tubule. Lamivudine and Abacavir 
have been implicated in Fanconi syndrome and Abacavir have been reported 
to cause immuno-allergic interstitial nephritis
[61].
  
 
Table 13 : POTENTIALLY NEPHROTOXIC ANTIRETROVIRALS 
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The major drugs implicated are tenofovir, atazanavir and indinavir 
[62] 
which 
are discussed here. 
TENOFOVIR 
               Tenofovir is the commonly used first line drug along with 
Lamivudine /Emtricitabine. It is an acyclic phosphonate  which is effective  
against  both  Hepatitis B and HIV infection ,frequently used in first line 
HAART regimens. It can cause generalized proximal renal tubular 
dysfunction ( fanconi,s syndrome ) which can manifest as :  glucosuria  
,bicarbonaturia , tubular proteinuria ,uricosuria,  aminociduria,  uricosuria, 
and phosphaturia. 
                  It is reported  that this  tubular toxicity is due to direct tubular 
cytotoxicity  by the drug or due to  DNA depletion in mitochondria  similar 
to  the  use  of  cidofovir  and  adefovir . This  proximal  tubular  dysfunction  
potentially  reversible  if  detected promptly and drug  is  withdrawn. 
                Mild toxicity is frequently asymptomatic but severe injury can 
cause ostemalacia with  bone pain and AKI.  TDF is reported  with  a  few 
,but high  risk of AKI, which is nonoliguric and may require dialysis 
[63].
 
However studies shows that there is no significant high risk of  
proteinuria,CKD and ESRD ,which requires dialysis in HIV patients treated 
with HAART 
[64,65] . 
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Table 14 :  SCHEME FOR MONITORING PROXIMAL TUBULAR FUNCTION 
DUTING TENOFOVIR THERAPY  : EACS GUIDELINES  
SCREENING TESTS FREQUENCY 
1.eGFR 
2.Urine protein/creatinine ratio  
3.Urine glucose 
4.Urine fractional excretion of phosphate 
5.Tubular proteinuria 
 (eg.retinol binding protein) 
 
Baseline  
3 monthly for 1 year 
Twice monthly thereafter 
Additional survey for proximal renal tubulopathy if any 1-5 present: 
 Serum bicarbonate and urinary pH ( bicarbonate < 21 and pH >5.5 
suggest RTA 
 Urinary fractional excretion of uric acid 
 Serum potassium and urinary potassium excretion 
 Consider DEXA scan if evidence of  renal phosphate wasting   
Consider stopping if : 
 Significant and sustained changes in 1 – 4 
 Syndrome of proximal renal tubular acidosis  
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 Progressive deterioration in tubular proteinuria 
 Lot of observational studies revealed that TDF induced renal damage is 
common in patients with multiple comorbid illness and is more frequent  in 
HIV positive   patients with associated conditions, shown in table  
Table 15 : PREDICTORS OF RENAL FUNCTION DECLINE WITH 
TENOFOVIR
[66] 
      
          Reduction  of  eGFR in TDF based regimen  have  been  reported. In 
the Johns Hopkins  study , Tenofovir treated patients have a greater decrease  
in  eGFR  than  in   treated with other regimens  (19 vs. 11 mL/min).
[67]
.       
            Approximately 70% of causes of TDF nephrotoxicity is observed 
with its concomitant use with Protease inhibitor due to unique mechanism. 
The MRP4 (multidrug  resistance  associated  protein-4), in the proximal  
tubules ,which secretes TDF into the urine is inhibited by PI/ritonovir ,which 
in turn leads to intracellular accumulation of TDF and increased nephrotoxic 
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effects 
[68]
.Concurrent use of NRTI, didanosine is not recommended as it 
enhance TDF toxicity
[57]. 
            In one  study consisting of  ∼140 subjects,  there is a greater decrease 
in GFR of  7-10 mL/ml in  tenofovir- boosted PI regimen compared with a 
tenofovir– nonnucleoside reverse-transcriptase inhibitor or non-Tenofovir -
containing regimen over 48 weeks period . 
[69] 
  
Fig 8 .Mechanism of action of Tenofovir  
 
 
 
               
Tenofovir is predominantly excreted  by  combination of glomerular filtration and active 
tubular secretion. It enters into the kidney through  organic anion transportess,OAT-1 and 
OAT-3 from the basolateral  side and  leaves  either via MRP2 and/or MRP4,which are P 
glycoprotein . MRP4 inhibition by PI/RTV  leads  to raised intracellular tenofovir  levels 
which may increase its nephrotoxic effects. MRP: multidrug resistant protein; OAT; 
organic anionic transporter; TFV : tenofovir PI/RTV : ritonavir-boosted protease inhibitor . 
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                  TDF is contraindicated in long-term diabetes sufferers, those with 
uncontrolled hypertension or renal failure and when the estimated 
glomerular filtration rate is <50 ml/min/1.73 m2. 
               Other nucleoside analogs like Lamivudine, Abacacir  , Stavudine 
and didanosine have also been reported to cause  Fanconi syndrome and 
nephrogenic  Diabetes  insipidus in few case reports . 
Table 16 : NRTI s dose adjustment for HIV infected patients with renal 
insufficiency
[70] 
AGENT NORMAL DOSE eGFR ( creatinine CL) 
Zidovudine(AZT) 300 mg PO BD 100 mg TDS PO 
Lamivudine 
(3TC) 
150 mg PO BD 30-49mL/min=150 mg OD 
15-29mL/min=100 mg OD 
 5-14mL/min=50 mg OD         
< 5mL/min=25 mg OD 
Stavudine (d4T) 30 mg PO BD 26-50mL/min=15 mg BD 
 < 26mL/min=15 mg OD 
Emricitabine 
(FTC) 
200 mg PO OD 30-49mL/min=200mg 48hr 
15-29mL/min=200mg 72 hr 
< 15mL/min=200 mg 96 hr 
Didanosine (ddl) <60 kg 250mg OD 
>60mg 400mg OD 
30-59 mL/min=200 mg OD 
10-29mL/min=150 mg OD 
< 10mL/min=100 mg OD 
lxxiv 
 
Tenofovir (TDF) 300 mg PO OD 30-49mL/min = 300mg 48 hr 
10-29mL/min= 300mg 72 hr 
<10mL/min= 300 mg once 
weekly 
Tenofovi(TDF)+ 
Emricitabine 
(FTC) 
1 capsule PO OD 30-49mL/min= 1 tablet every 
48hr 
        < 30mL/min not 
recommended 
Abacavir ABC) 300 mg PO BD No need for dose adjustment 
 
 Table 17 : NNRTI’s dose adjustment for HIV infected patients with 
renal insufficiency
[70] 
AGENT NORMAL DOSE eGFR(Creatinine 
CL) 
Delavirdine (DLV) 400 mg PO TDS No dose adjustment 
necessary 
Efavirenz (EFV) 600 mg PO OD  No dose adjustment 
necessary 
Efavirenz (EFV)-
Tenovofir (TDF)-
Emtricitabine(FTC) 
600 mg PO OD Not recommended if 
CrCl <50 mL/min. 
Instead use the 
individual drugs of 
the fixed-dose 
combination and 
adjust TDF and FTC 
doses . 
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Nevirapine (NVP) 200 mg PO BD No dose adjustment 
necessary 
 
 
INDINAVIR  
             In Indinavir therapy , less than 20% of  individuals develop indinavir 
crystalluria. Indinavir renal syndrome (IRS ) can manifests silent crytalluria, 
symptomatic crystalluria with dysuria/ pain in flanks  , nephrolithiasis and 
slow onset scarring tubulointerstitial nephritis associated with pyuria. 
           In nephrolithiasis, ultrasound KUB shows only mild to moderate 
obstructive hydrocephalus with no calculi, because of radiolucent stones. 
Cofactors in IRS are  fluid deprivation, acyclovir  coadministration, 
alteration in the dose of indinavir
[71]
 
           Tubular crystals, dilatation of tubules  and necrosis associated with  
eosinophillic infiltrates in interstitium  and scarring can develop in chronic 
renal impairment. In 32% of patients on indinavir therapy , persistent 
leucocyturia is common. 
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           HIVMA- IDSA guidelinesrecommends intake of atleast 1.5 L of 
water per day iin patients receiving indinavir., and periodic monitoring of 
urine for pyuria and creatinine should be done in the first 6 months of 
treatment
[71]
. 
          Once nephrolithiaisis develops , indinavir therapy can be resumed 
after treating renal stones ,unless there is associated hypertension, pyuria, a 
elevated serum creatinine or if rhabdomyolysis present. 
Table 18 : Protease,Integrase and Entry inhibitor dose 
recommendations in renal failure
[70] 
PROTEASE INHIBITOR 
AGENT NORMAL DOSE eGFR ( Creatinine CL) 
Atazanavir ( ATV) 400 mg PO OD No dose adjustment necessary 
for patients not requiring HD 
Fosamprenavir 
(FPV) 
1400 mg PO BD No dose adjustment necessary 
Indinavir (IDV) 800 mg PO TDS No dose adjustment necessary 
Ritonavir (RTV) 600 mg PO BD No dose adjustment necessary 
Lopinavir/ritonavir 
(LPV/r) 
400/100 mg PO 
BD or 
800/200 mg PO 
OD 
Avoid OD dose in patients on 
HD 
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Nelfinavir (NFV) 1250 mg BD No dose adjustment necessary 
Saquinavir (SQV) 1200 mg TDS No dose adjustment necessary 
Tiprinavir (TPV) 500 mg PO BD No dose adjustment necessary 
 
 
 INTEGRASE INHIBITOR 
Raltegravir (RAL) 400 mg BD Po No dose adjustment 
necessary 
 
 ENTRY INHIBITOR 
Enfuvirtide (T20) 90 mg  s.c BD No dose adjustment 
necessary 
 
CCR5 Antagonist  
Maraviroc (MVC) The dose differs based 
on concomitant drugs 
and its  interactions 
 150mg, 300mg o r  
600mg 
CrCl <30mL/min or HD: 
should reduce Maraviroc 
and CYP3A inhibitor only 
if potential benefits 
overweighs the risk 
 
ATAZANAVIR 
                 Atazanavir is the commonly used once daily protease inhibitor 
which is well tolerated. Like indinavir it has the potential to crystallize and 
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form calculi , much less frequently ( around 1%). Tubulointerstitial nephritis 
with atazanavir is correspondingly very rare. 
 
 
RENAL EFFECTS OF COMMONLY USED DRUGS IN HIV 
PATIENTS (Non-ARVs) : 
Amphotericin B, foscarnet, high dose acyclovir, cidofovir  and pentamidine 
shows nephrotoxic potential an all these should be administered with 
caution. 
 Amphotericin B – Renal tubular acidosis, 
hypokalemia,bicarbonaturia, decrease serum erythropoietin and increased 
creatinine value. Liposomal preparation is less nephrotoxic. 
  Cidofovir – Dose dependent nephrotoxicity (  bicarbonaturia, 
glycosuria, phosphoturia, nephrogenic diabetes insipidus and polyuria  ) 
which is corrected by adequate hydration and probenicid. 
 Foscarnet - hypocalcemia, hypophosphatemia, hypomagnesemia, 
        Hyperphosphatemia, hypokalemia and seizures.  
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Ciprofloxacin, Acyclovir, sulphonamides- intratubular precipitation of 
crystals leads to ARF . 
 
 
 
RENAL DIALYSIS  IN HIV POSITIVE  PATIENTS 
                     Survival of HIV positive patients with ESRD , who requires 
either hemodialysis or peritoneal dialysis is comparable to those with HIV 
negative individuals on dialysis with 1 year survival rates of 74%
[72] 
                      Based on CDC recommendations, Renal dialysis can be safely 
performed in  HIV positive  patients 
[73]
.The choice on the mode of dialysis 
either peritoneal dialysis or   hemodialysis  is not predicting the overall 
survival  among HIV patients with ESRD 
[72]. 
 HIV-1 viral replication is not 
increased by hemodialysis induced cytokine stimulation.  
                    For hemodialysis , Native arteriovenous fistulae are the 
preferred access , because of good  patency, less complication rates , lower 
rates of infection than synthetic grafts .In native fistulas, thrombus-free 
survival for native  fistulas  is similar  to that observed in HIV negative 
persons. 
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                   In HIV-infected patients on peritoneal dialysis, incidence of 
peritonitis has been reported in case series. In pre –ART era, one large series 
with 39 HIV patients on peritoneal dialysis observed to have an increased 
risk of peritonitis due to pseudomonas and fungi.   
            Peritoneal dialysate fluid also found to have HIV virus, which should 
be discarded and handled safely . Continuous ambulatory peritoneal dialysis 
is successfully used in HIV patients, though it is used rarely. 
 
RENAL TRANSPLANTATION 
               In pre- ART era, there was a varying outcomes in HIV positive 
renal transplant patients, including long term survival and and rapid 
progression of HIV because of immunosupression.  
              In post ART era as there was a dramatic reduction in HIV induced 
morbidity and mortality, immunosupression is on major concern.  In fact, 
there may be  beneficial effect, in immunosupression by reducing the pool of 
activated T cell targets for new HIV infection, reducing  immune activation, 
inhibiting HIV replication or interacting synergistically with antiretroviral 
agents. 
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            Few case reports showed that the survival rates are equal in HIV 
positive and non HIV transplant recipients, however high rates of graft 
rejects are reported in HIV infected kidney transplant recipients. 
 
PATHOGENESIS OF HIV INFECTION ON KIDNEY  
            Renal involvement is not well understood in HIV infection . The 
mechanism for acute renal failure is somewhat similar to in non- HIV 
infected individuals, so better understood, but for chronic kidney diseases ( 
Immune complex disease, FSGS and microangiopathies ) ,the basis remains 
obscure. 
            However with  recent observations  and research , a clearer picture is  
emerging. It   is  helpful  to  highlight  several  important  observations  and 
consolidate  various  evidences.   
            Viral activity and replication have been demonstrated in renal tissue.  
Glomerular epithelium , tubular cell, mesangial and endothelial cells have 
been shown to demonstrate viral activity and replication. 
ROLE OF HIV -1 INFECTION IN AFFECTING RENAL CELLS :   
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            HIV can directly infects the kidneys is evident from the HIV –
transgenic mice and its association with advanced HIV disease . Specific 
gene expression in HIV induces the cellular immune pathways in the host 
which are responsible for pathogenesis of   HIVAN. 
            The mechanism by which the virus affect the renal cells remains 
obscure. It may be because of lymphocytes which affect the epithelial cells 
via transcytosis. Studies showed the genetic variability of gp120, influences 
the susceptibility of renal epithelial cells for infection in HIV positive 
individuals. 
            Another  proposed  mechanism for  renal involvement  is due to the 
lack of  microparticles  like  coreceptors  for CCR5 , which is required for 
virus entry into the cell.  An in vitro model , these coreceptors on cell 
surface helps in allowing virus entry by transferring CCR5 into the cell. 
            Though in situ hybradiztion and polymerase chain reaction suggested 
the involvement of  both  podocytes  and  epithelial cells ,there is conflicting 
evidence about the involvement of mesangial cells. 
             The  role of renal dentritic cell in HIV infection was studied. These 
cells are  useful  for binding, transfer  and dissemination of virus  to various 
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nonlymphoid  and  lymphoid  tissues and also play an important role in 
infecting renal cells.  
              An in vitro model suggests the C-type Leptin receptor DEC-205 
mediate the internalization of HIV into the renal tubular cells which lack 
CCR5 ,CXCR4 and CD4. 
                  Thus lot of increasing evidence suggests that the renal cells 
support viral infection. 
ROLE OF VIRAL PROTEINS  
                      The transgenic mice which express particular combinations of 
viral products as proteins  are  lacking  in  pol  and  gag  genes ,so  the  
generation  of  complete  virions  are  affected. 
                     HIV gene products induce direct cell cycle progression, and the 
apotosis of renal epithelial cells was mediated by caspase activation and Fas 
up-regulation in both HIVAN specimens and murine models. 
                In HIVAN , Fas mediated apoptosis is dependent on gp120 and 
gp160 is responsible for mesangial cell apoptosis and and downregulation of 
Bcl-2 ,which is a antiapoptotic protein.  
HOST FACTORS 
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                        HIVAN was first identified in African Americans , the 
predilection of disease in African Americans is due to increase frequency of 
” risk alleles “ which suggest a strong genetic association.  The susceptibility 
focus was identified in Tg26 mouse model , which induce latent 
perturbations in podocyte gene expression network .Similarly in humans, 
alleles on MYH9 locus ( a functional gene expressed in glomerular 
podocytes) of chromosome 22 suggests a higher frequency of  HIVAN 
among blacks. However, recent researchers have noted that the MYH9 gene 
is located next to the APOL-1 gene which is more significantly associated 
with ESRD than all previously reported variations in MYH9 gene . 
 
 
 
 
 
 
 
lxxxv 
 
Fig 9 : PATHOGENESIS OF HIV INFECTION  
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                           METHODOLOGY 
SOURCE OF STUDY :  
         Newly  diagnosed  HIV positive   patients  who are  attending  ART  
clinic  and  admitting  in  Medical  wards  at  Coimbatore  Medical  College  
Hospital . 
DESIGN OF STUDY       : Cross sectional study 
PERIOD OF STUDY       : August 2013 to June 2014 
SAMPLE SIZE            : 100 patients 
STUDY POPULATION  :     
              100  patients  who  are  attending  ART  clinic  and  admitting  in  
Medical  units  at  Coimbatore  Medical  College  Hospital  were  randomly  
selected  as  per  the  inclusion  and  exclusion  criteria.  Out  of   these ,  44   
were  men  and    56  were   women.  The mean  age  of  subjects  was   40.8  
years  with  a  range  of     20-81    years. Written  informed  consent  was  
obtained  from  each  HIV positive  patients  enrolled  in the study . 
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INCLUSION CRITERIA :  
 All  newly diagnosed  adult  HIV  positive  patients  as  per  the  NACO  
guidelines  , who was  started on HAART and  who  are  attending  ART 
clinic and also  patients who were  admitted  in Medical  units  at  
Coimbatore  Medical  College  Hospital. 
EXCLUSION CRITERIA : 
 Patients  with  Chronic  renal  failure  
 Patients  with  diagnosed  systemic  causes  of  renal  diseases  
( eg., SLE ,Systemic Sclerosis,  Rhematoid arthritis, and  other  
rheumatological  &  connective tissue disorders ) 
 Patients  who  are  known  Diabetic   or  Hypertensive  or  any  other  
comorbid  illness . 
 Patients  with  associated  Hepatitis B/ C virus  infection 
 Pregnant women  and  children  age less than  15  years 
 Patients  with  poor  adherence  ( > 80 % ) 
 Patients  receiving  other  nephrotoxic  drugs / NSAIDS. 
 Pregnancy 
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DATA COLLECTION 
The 100 newly diagnosed HIV positive  patients were included in the study. 
Detailed history – including  duration  of  disease, any past history of  
antiretroviral drug  and  other medications  , treatment regimen started ,  
WHO staging of  the HIV disease  were obtained . Patients were  examined  
in  detailed for assessing  any  symptoms  and  signs  of   renal failure . 
Blood samples were taken for screening baseline renal function for  urea,  
creatinine  and  also for CD4 count . Baseline eGFR was calculated using 
Cockgroft – Gault equation . Patients were followed up over a period of 10 
months and any opportunistic infections  developed  among patients during 
study period was noted. At the end of 10 months, patients were assessed  for 
Urea , Creatinine , CD4 counts by drawing blood samples and eGFR was 
calculated using CG formula. Urine routine  and USG KUB was done . 
STATISTICAL ANALYSIS : 
  All the dates were entered in a data collection sheet in an Excel format 
and analysed using SPSS Software. Numerical values were reported using 
mean and standard deviation or median. Categorical values are reported 
using number and percentages. Probability value (p) value less than 0.05 was 
considered a statistically significant. 
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                                           RESULTS  
The  present  study is a prospective study . Cross- sectional data for  
100  patients  diagnosed  to  have  HIV infection  who  was  attending  ART 
clinic  and  Medical units at CMCH  during the period of August 2013 to 
June 2014 , were recruited for the purpose of this study. 
TABLE 19  : CHARACTERISTIC OF  STUDY  POPULATION  
                                  CHARACTERISTICS  
TOTAL  NO  OF SUBJECTS            -  100 
        AGE                                    -   20 - 81 
    MALE                                    -   44 
    FEMALE                               -   56 
STAGING of  KIDNEY DAMAGE  BASED  ON  eGFR ( END 
of Study) 
     GFR Normal      >90   ml/min/1.73m
2
          -  21 
      GFR  Mild   60 – 90   ml/min /1.73m
2
           -  37 
      GFR Mod – Sev   < 60   ml/min/1.73m2        - 42  
WHO  CLINICAL  STAGING AFTER ART  
                                      T1                         -    67 
                                      T2                          -  7 
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                                      T3                         -  12 
                                      T4                          - 14 
        HAART  REGIMEN  
                                  TLN                        - 28 
                                  TLE                        - 42 
                                  ZLN                       - 22 
                                  ZLE                        - 8  
 
                          A total of 100 patients were selected for the study .Of the 
100 HIV infected patients , starting ART at CMCH ,44 males and 56 
females. Among them patients were distributed across the age spectrum of 
20 to 81 years.  Females accounts for  56% of study population and the mean 
age was 40.08. The patients were distributed in all the clinical stages of HIV 
disease from T1 to T4.  
                        And four types of regimen was taken by the patients TLN ( 
28), TLE( 42), ZLN ( 22) ,ZLE (8). Out of 100 patients , at the end of study 
21 % patients  with Normal GFR (>90), 37%  with mild reduction (60-90) 
and 42% with mod- severe reduction in eGFR ( <60), ten months after 
initiating ART, with majority of GFR decline in Tenofovir based regimens . 
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TABLE  20   : GENDER  DISTRIBUTION  
Gender Frequency % 
Female 56 56 
Male 44 44 
Total 100 100 
 
 
In this present study , majority are females with 56% of study 
population and males constitutes 44% of study population. 
 
Female, 56 
Male, 44 
GRAPH 3  -  GENDER DISTRIBUTION  
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TABLE 21 : RELATIONSHIP BETWEEN GENDER AND 
eGFR_E 
Relationship between Gender and eGFR_E 
                          eGFR_E 
SEX Mean Minimum Maximum No of 
Cases 
Female     64.91       24    129      56 
Male     74.83      32.4    143      44 
Total     69.28       24    143     100 
 
 
                                    ANOVA 
eGFR_E           
  
Sum of 
Squares 
     
df 
Mean Square        F P 
Value 
Between 
Groups 
2426.471991 
      
1 
2426.471991 3.6773460 0.06 
Within 
Groups 
64664.63995 
    
98 
659.8432648 
    
Total 
67091.11194 
    
99       
 
The average eGFR for female is 64.91 and for male is 74.83 
The ANOVA test indicates that the difference of average in eGFR between 
male and female is not statistically significant 
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TABLE 22 :  DISTRIBUTION OF CASES ACCORDING TO 
ESTIMATED GLOMERULAR FILTRATION RATE  BEFORE AND 
AFTER  ART  
Category 
 (eGFR ml/min) 
eGFR_ B 
( Baseline ) 
eGFR_E 
( End of 10
th
 
mon) 
Difference  
eGFR ( B- 
E) 
 < 60(Mod-sev) 22 42 20   
60-90 ( Mild ) 46 37 9 
 >90 ( Normal ) 32 21 11 
Total  100 100 40 
 
 
The overall average mean eGFR at the end of study in this sample is 69.28 
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Graph 4 : DISTRIBUTION OF CASES BASED ON eGFR 
eGFR _ B
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xciv 
 
In this study , before starting ART most patients , 46 % were in 60-90 
category and 32% were in >90 category and at the end of study after 
HAART initiation , 79% of patients  were in eGFR < 90 ml/min . Of which , 
42 % in <60  (mod – severe ) and 37% in 60-90 eGFR( mild reduction ) . 
Approximately 20 % of patients with normal baseline eGFR falls into severe 
decline in eGFR after ART introduction . 
TABLE 23 :     AGE DISTRIBUTION  
Age in years                          Total 
20 – 25 6 
26 -30 14 
31 -35 24 
36 – 40 14 
41 – 45 16 
46 – 50 11 
51- 55 6 
56 – 60 7 
>60 2 
 
 
24 
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Graph 5 : Age Distribution 
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Most of the patients in the study are in the age group of 31  to 45 ( 3
rd
 and 4
th
 
decade) with majority in 31 – 35 ( 24 %). The mean age in the study was 40.02. 
TABLE 24 : RELATIONSHIP BETWEEN AGE AND eGFR  
Relationship between AGE and eGFR_E (No of Cases) 
         eGFR_E                 < 60 60 -90 > 90        Total 
AGE 
20 - 25 3 1 2 6 
26 -30 4 4 6 14 
31 -35 11 7 6 24 
36 - 40 6 5 3 14 
41 - 45 7 6 3 16 
46 - 50 4 7 0 11 
51 - 55 1 5 0 6 
56 - 60 4 2 1 7 
> 60 2 0 0 2 
Total 42 37 21 100 
 
Symmetric Measures 
    
Correlation 
Value 
Asymp. Std. 
Errora 
Approx. Tb (P Value) 
Interval by 
Interval Pearson's R 
-0.20 0.09 -2.025 0.046 
Ordinal by 
Ordinal 
Spearman 
Correlation 
-0.16 0.099 -1.57 0.12 
N of Valid 
Cases   
100 
      
 The correlation between eGFR_E and AGE is negative .It appears almost 
significant with a P value of 0.046. . Majority  decline in  eGFR occur in the 
age group of 31- 35 with category < 60 in 11 patients ( 26%). 
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Age Groups 
GRAPH 6: DISTRIBUTION OF AGE AND EGFR_E (AS PER 
FREQUENCY) 
< 60 60 -90 > 90 Linear (< 60) Linear (60 -90) Linear (> 90)
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    TABLE 25 : COMPARISON BETWEEN eGFR ACROSS AGE 
Dependent 
Variable 
M
ea
n 
A
ge 
 (I) 
eGFR E 
(J) 
eGFR_E 
Mean 
Differenc
e (I-J) 
Std. 
Error 
    P  
Value 
AGE 
41.12 
< 60 
60-90 -0.935 2.405 0.92 
42 > 90 6.881* 2.85 0.046 
42.05 
60-90 
< 60 0.935 2.405 0.92 
37 > 90 7.816* 2.914 0.023 
34.24 
> 90 
< 60 6.881* 2.85 0.046 
21 60-90 -7.816* 2.914 0.023 
 
              This  table  indicates  that  at  eGFR ( at the end of study )  greater 
than  90 which is normal kidney function , has significantly lower average 
age when compared to other two categories, where there has mild to 
moderate kidney damage occurs . However  between  the categories of  less 
than 60 and 60-90, the average age levels do not seems to be significant.  
             So , this study shows that significant renal damage can occur in the 
higher age group of when compared to lower average age groups.  
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 TABLE 26 : COMPARISON OF  eGFR_E  ACROSS 
WEIGHT 
Dependent 
Variable 
Mean 
WEIGHT 
(kg) 
(I) 
eGFR_E 
(J) 
eGFR_E 
Mean 
Difference 
(I-J) 
Std. 
Error 
P 
Value 
WEIGHT 
(KG) 
46.69 
< 60 
60-90 -3.174 1.355 0.055 
42 
> 90 -2.786 1.606 0.198 
49.86 
60-90 
< 60 3.174 1.355 0.055 
37 
> 90 0.389 1.642 0.97 
49.48 
> 90 
< 60 2.786 1.606 0.198 
21 
60-90 
-0.389 1.642 0.97 
 
This table indicates that between either of this three categories ,the 
weight does not appear to be significantly  different and  P value is > 0.05 
 
In this present study, the mean weight of the patients were 48.45 Kg , 
with a minimum of  27 Kg and a maximum of 58 Kg. 
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TABLE 27 : COMPARISON OF eGFR_E  ACROSS  UREA.  
Dependen
t Variable 
Mean 
UREA
_E 
(I) 
eGFR_
E 
(J) 
eGFR_E 
Mean 
Difference 
(I-J) 
Std. 
Error 
P 
Value 
UREA_E 
( End of 
study) 
29.9 
< 60 
60-90 2.418 1.174 0.104 
    42 
> 90 
3.381* 1.391 0.044 
27.49 
60-90 
< 60 
2.418 1.174 0.104 
     37 
> 90 
0.963 1.422 0.777 
26.52 
> 90 
< 60 
-3.381* 1.391 0.044 
     21 
60-90 
-0.963 1.422 
0.777 
 
  
 
                This table indicates that between less than 60 and greater than 90 
eGFR_E, the average levels of Urea_E is different. Average levels of UREA_E 
is higher for < 60 eGFR_E as compared to >90 eGFR_E with P value of 0.044 . 
                No significant difference of levels of  Urea  is indicated ,between 60-
90 category and < 60 category of eGFR and also between 60-90 and > 90 
category. 
         Mean urea was 28.3 mg/dl with minimum of 16 and maximum of 44. 
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TABLE 28 : COMPARISON OF eGFR  ACROSS CREATININE  
Dependent 
Variable 
Mean 
CREATI
NINE 
(I) 
eGFR
_E 
(J) 
eGFR
_E 
Mean 
Differen
ce (I-J) 
Std. 
Error 
P 
Valu
e 
CREATINI
NE 
 ( End of 
study) 
1.26 
< 60 
60-90 .3349* 0.0566 0 
42 
> 90 .5476* 0.0671 0 
0.93 
60-90 
< 60 -.3349* 0.0566 0 
37 
> 90 .2127* 0.0686 0.007 
0.71 
> 90 
< 60 -.5476* 0.0671 0 
21 
60-90 -.2127* 0.0686 0.007 
 
  This   table  indicates  that  between  all  three  categories  of  eGFR at the end 
of study ,  the  average  levels of  Creatinine  are  different 
                       In  other  words , average  levels  of  creatinine  is  significantly  
higher  for  <60 eGFR  as  compared  to 60-90 and  >90  eGFR levels.  Also  
creatinine  average  is  higher  for  60-90  eGFR_E  as  compared  >90  eGFR_E 
levels. In the present study , it shows that increase in creatinine value from 
baseline is directly proportional to decline in eGFR from 90 – 60 and < 60.  
Mean creatinine value is 1.028 with minimum of 0.5 and maximum of 1.8. 
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Table 29 : DISTRIBUTION OF CASES ACCORDING TO 
URINE ALBUMIN  
Microalbuminuria No of patients Percent 
Nil 53 53% 
Trace 24 24% 
1+ 12 12% 
2+ 8 8% 
3+ 3 3% 
Total 100 100.0 
 
 
In the present study , albuminuria was noted in 47 patients( 47%).Of the 47 ,who 
had albuminuria ,24 had Trace, 12 had 1+,8 had 2+ and 3 had 3+ albuminuria. 
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Graph 7 : DISTRIBUTION OF URINE 
ALBUMIN 
ci 
 
Symmetric Measures 
    
Value Asymp. Std. 
Errora 
Approx. 
Tb 
Approx. 
Sig. 
Interval by 
Interval Pearson's R 
-0.609 0.049 -7.599 0.000 
Ordinal by 
Ordinal 
Spearman 
Correlation 
-0.682 0.058 -9.243 0.000 
N of Valid 
Cases   
100 
      
       
TABLE  30 : CORRELATION BETWEEN URINE ALBUMIN 
AND eGFR_E 
Relationship between URINE_ALB and eGFR_E 
 (No of Cases) 
 eGFR_E < 60 60 -90 > 90 Total 
Urine 
ALB 
Nil 6 27 20 53 
Trace 15 9 0 24 
1+ 10 1 1 12 
2+ 8 0 0 8 
3+ 3 0 0 3 
Total   42 37 21 100 
 
 
 
  
 
 
 
 
 
  
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In the present study , there was a negative correlation between Urine 
albumin and eGFR at the end of study  and the P value is significant 0.00 .  
 This study shows that, as the grades of  urine albumin increases, eGFR 
declines . Category with eGFR < 60 ml/min shows high albuminuria with 
23% in 1+ ,19% in 2+ and 7% in 3+ range. 
 
-10
-5
0
5
10
15
20
25
30
Nil Trace 1+ 2+ 3+
Fr
eq
u
en
cy
 u
n
d
er
  e
G
FR
_E
 
URINE_ALB 
Graph 8 : Relationship of URINE_ALB and eGFR_E (as per 
frequency) 
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TABLE 31  : DISTRIBUTION OF USG –KUB  
Distribution of USG_KUB 
USG_KUB Frequency Percent 
Normal 85 85% 
R*/C 15 15% 
Total 100 100% 
 
 
In the present study , renomegaly / contraceted  kidney  was found in 
15 patients (15%) and  85 patients ( 85%) had normal sized kidneys . 
Normal , 85 
R*/C , 15 
Graph 9 : USG_KUB DISTRIBUTION 
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TABLE 32  : DISTRIBUTION OF USG- KUB ACROSS 
eGFR_E. 
eGFR_E 
USG_KUB < 60 60 -90 > 90 Total 
% 
 Normal  27 37 21 85 
Renomegaly/ 
Contracted
 
15 0 0 15 
    Total 42 37 21 100 
Graph 10:  
 
Among 15 % of patients with abnormal kidney size , almost 
all patients were come under the category of e GFR < 60 ml/min.  
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Table 33 : DIFFERENT TYPES OF ART REGIMEN 
TAKEN BY THE PATIENT DURING STUDY  
 
REGIMEN NO OF PATIENTS PERCENTAGE 
TLN  ( A) 28 28% 
TLE  ( B ) 42 42% 
ZLN ( C)   22 22% 
ZLE  (D) 8 8% 
TOTAL 100 100% 
 
 
In present study , 4 types of ART regimen was taken up by the 
patients with TLN (28%) , TLE (42% ), ZLN (22%) and ZLE (8%) . 
Majority of patients are in Tenofovir based regimen .  
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Graph 11: DISTRIBUTION OF ART 
REGIMEN  
TLN
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TABLE 34 ; RELATIONSHIP BETWEEN THE ART 
REGIMEN AND eGFR_E DURING STUDY 
 
Relationship between REGIMEN and eGFR_E (No of Cases) 
 eGFR_E < 60 60 -90 > 90 Total %  
REGIMEN TLN ( A) 13 11 4 28 28%  
70% TLE ( B) 25 15 2 42 42 % 
ZLN (C) 1 8 13 22 22%  
30% ZLE ( D) 3 3 2 8 8% 
Total  42 37 21 100 100%  
 
 
Among the ART regimen used in this study , Tenofovir based regimen 
( AB ) accounts for 70 cases (  70%) and Zidovudine based regimen (CD ) 
accounts for 30% of cases. 
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Relationship between REGIMEN and eGFR_E 
                        eGFR_E 
REGIMEN eGFR_E Mean Mini Max No of 
Cases 
% of Cases on 
Total Sample 
AB 
Tenofovir 
based 
<= 90 56.7 24.0 88.4 64 64% 
> 90 103.5 90.6 124.6 6 6% 
Total 60.7 24.0 124.6 0 70% 
CD 
Zidovudine 
based 
<= 90 67.8 37.8 87.6 15 15% 
> 90 110.6 94.6 143.0 15 15% 
Total 89.2 37.8 143.0 30 30% 
Total 
<= 90 58.8 24.0 88.4 79 79% 
> 90 108.6 90.6 143.0 21 21% 
Total 69.3 24.0 143.0 100 100%                                 
 
      eGFR_E 
    Tukey HSD 
  
 Multiple comparisons Regimens 
  
  
(I) 
REGIMEN_2_eGFRE_2 
(J) 
REGIMEN_2_eGFRE_2 
Mean 
Difference 
(I-J) 
Std. 
Error 
P Value 
          
AB <= 90 
AB > 90 -46.76 6.79 0.00 
CD <= 90 -11.12 4.56 0.08 
CD > 90 -53.92 4.56 0.00 
AB > 90 
AB <= 90 46.76 6.79 0.00 
CD <= 90 35.64 7.68 0.00 
CD > 90 -7.16 7.68 0.79 
CD <= 90 
AB <= 90 11.12 4.56 0.08 
AB > 90 -35.64 7.68 0.00 
CD > 90 -42.80 5.81 0.00 
CD > 90 
AB <= 90 53.92 4.56 0.00 
AB > 90 7.16 7.68 0.79 
CD <= 90 42.80 5.81 0.00 
 
     This multiple comparisons table indicates  
 
 
 
Regimen AB with eGFR <90 is having significantly lower eGFR as compared to AB with eGFR > 90 
Regimen AB with eGFR < 90 is having significantly lower eGFR as compared to CD with e GFR .90 
Regimen AB with eGFR > 90 is having significantly lower eGFR as compared to CD with e GFR < 90 
Regimen CD with e GFR < 90 is having significantly lower GFR as compared to CD with eGFR > 90 
TENOFOVIR BASED REGIMEN TREATED PATIENTS  HAS  SIGNIFICANTLY  LOWER  EGFR COMPARED 
TO ZIDOVUDINE BASED REGIMEN .  
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TABLE 35 : WHO CLINICAL STAGING OF 
PARTICIPANTS IN STUDY  
 
STAGE No of patients % 
T1 67 67% 
T2 7 7% 
T3 12 12% 
T4 14 14% 
Total          100            100% 
 
 
 
In this present study ,  majority of  HIV patients were in WHO clinical 
stage T1 (67%) , and 7 % in T2 , 12% in T3 and and 14 % in T4. 
 
67% 
7% 
12% 
14% 
Graph 13 : Who clinical staging of 
participants 
T 1 T 2 T 3 T 4
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TABLE  36  : CORRELATION BETWEEN WHO CLINICAL 
STAGING AND eGFR_E 
 
Relationship between WHO CLINICAL STAGE and eGFR 
(No of Cases) 
  eGFR_E < 60 60 -90 > 90 Total 
STAGE T1 24 28 15 67 
T2 1 2 4 7 
T3 7 4 1 12 
T4 10 3 1 14 
Total   42 37 21 100 
 
 
Symmetric Measures 
    
Correlation 
Value 
Asymp. 
Std. 
Error 
Approx. 
Tb 
P Value 
Interval 
by 
Interval 
Pearson's 
R 
-0.239 0.088 -2.436 0.017 
Ordinal 
by 
Ordinal 
Spearman 
Correlation 
-0.203 0.096 -2.054 0.043 
No of 
Valid 
Cases   
100 
    
  
cx 
 
 
In the present study , there was a negative correlation between WHO 
clinical stage and eGFR and the P value is 0.017 which is significant . As the 
stage of the disease increases decline in eGFR also increases . In T4 stage 
out of 14 cases ,10 cases (71%) are in < 60 category . but in T1 out of 67 
,only 24 cases (36%) are in < 60 category. 
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GRAPH 14 : DISTRIBUTION OF WHO  STAGE AND EGFR_E (AS 
PER FREQUENCY) 
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TABLE 37  :  CORRELATION BETWEEN OI’ S AND e GFR_E 
 
Relationship between OIS and eGFR_E (No of Cases) 
   
eGFR_E 
 
< 60 
 
60 -90 
 
> 90 
 
Total 
OIS No 20 21 8 49 
PT  
3 
 
7 
 
2 
12 
Acute GE 2 1 3 6 
Tb Meningitis 1 1 0 2 
HZ 3 2 2 7 
Tb Pleural effusion 2 0 1 3 
CNS 
Toxoplasmosis 
2 0 0 2 
Tb lymphadenitis 0 0 2 2 
OC+ HIV 
myelopathy 
1 0 0 1 
Tb spine 0 1 0 1 
OC 0 0 2 2 
SEBORRHOEA 1 0 1 2 
PPE 1 2 0 3 
PCP 0 1 0 1 
PT+PCP 4 0 0 4 
PT+OC 0 1 0 1 
CMV RETINITIS 1 0 0 1 
HIV Myelopathy 1 0 0 1 
Total   42 37 21 100 
 
 
Symmetric Measures 
    
Correlation 
Value 
Asymp. 
Std. Error 
Approx. 
Tb 
P Value 
Interval by 
Interval 
Pearson's 
R 
-0.091 0.094 -0.908 0.366 
Ordinal by 
Ordinal 
Spearman 
Correlation 
-0.029 0.102 -0.291 0.772 
No of Valid 
Cases   
100 
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In the present  study ,there was no correlation between opportunistic 
infections and eGFR at  the end of study is visible  from  the  table .Also P 
value is not significant. 
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GRAPH 15 : DISTRIBUTION OF OIS AND EGFR_E (AS PER 
FREQUENCY) 
< 60 60 -90 > 90
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TABLE 38  : CORRELATION BETWEEN BASELINE CD4 COUNT  
AND eGFR  
 
Relationship between CD4_COUNT_B and eGFR_B (No of 
Cases) 
 
    eGFR_B Total % 
    < 60 60 -90 > 90    
CD4_COUNT_B 
P (<100 ) 4 11 3 18 18% 
Q( 100-200) 10 14 6 30 30% 
R( >200 ) 8 21 23 52 52% 
Total   22 46 32 100  
 
 
In this study, baseline CD4 count less than 200 was noted in 48% , Of 
these 18 patients had < 100 count  and 30 patients had 100 to 200 count 
.Majority of patients with decline in CD4 count <200  are in eGFR 60-90 
category. 
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TABLE 39 : CORRELATION BETWEEN CD4 COUNT AND eGFR  
AT THE END OF STUDY 
 
Relationship between CD4_COUNT_E and eGFR_E (No of Cases)  
    eGFR_B Total  
    < 60 60 -90 > 90    
CD4_COUNT_E 
P( <100) 1 1 0 2   2% 
Q( 100-200) 11 6 4 21 21% 
R ( >200) 30 30 17 77 77% 
Total   42 37 21 100  
 
 
In this study , CD4 count at the end of study which is less than 200 
were noted in 24 % of patients .Of which 2 patients had < 100 and 21 
patients had 100 to 200 CD4 counts. Majority of patients with decline in 
CD4 count <200 are in less than 60 eGFR category. 
1 1 0 
11 
6 
4 
30 
30 
17 
0
5
10
15
20
25
30
35
40
45
< 60 60 -90 > 90
N
o
 o
f 
C
D
4
_
C
o
u
n
t_
E
 C
a
s
e
s
 
eGFR_E 
G R A P H  1 7  :  D I S T R I B U TI O N  O F  C D 4 _ C O UN T _ E  
A C R O S S  E G F R _ E  
P Q R
cxv 
 
                              DISCUSSION  
                  A total of  100  patients  diagnosed to have HIV infection were 
recruited for this study  . They were recruited from ART clinic ( 90% data ) 
and Medical Units at Coimbatore Medical College Hospital during the 
period of August 2013 to June 2014 over 10 months after fulfilling inclusion 
and exclusion criteria. 
                      In 100 patients , about 79% of  HIV infected patients starting 
ART in our setting at CMCH  had evidence of renal dysfunction , with 
reduced eGFR of grade 2 ( 60-90ml/min) in 37 % and eGFR  grade 3 or less 
( <60ml/min ) in 42 % of study population. These patients had no known 
preexisting renal disease or risk factors for renal dysfunction aside from HIV 
infection. These high rates of renal dysfunction were confirmed by the 
finding that over 47 % of patients had detectable microalbuminuria.  
                      The finding that majority of renal dysfunction may be  present 
in HIV –1  infected outpatients initiating ART has important ramnifications  
given the increasingly widespread use of  Tenofovir , a  first line regimen  
recommended by WHO with known renal toxicity. In our study 70% of 
patients were in Tenofovir based regimen. 
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                  Our data suggest that low eGFRs which we observed reflect the  
true renal disease because patients with low eGFRs were also more likely to 
have high grade albuminuria . 
Age  and  Gender  distribution of cases : 
                    Most of the patients in the present study were females in the age 
group of     31-40  (56%) and the mean age of the patients in the present 
study was 40.08 
 
The mean age was more or less similar in all these studies .                                
 
STUDY  MEAN AGE GENDER PREDOMINANCE  
Oche 
O.Agbaj.et.al 
38.8   Female  
Rawlings Mb 
et.al  
37.9 Male  
Longo Ab et.al  43  Female 
Lene Ryam et.al  39 Male  
DART trial 
[74] 
37 Female 
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Distribution of cases according to eGFR 
                 In the present study , the baseline eGFR in majority of patients 
comes under category 60-90 and  ten months after intiation of HAART , 
majority of patients falls under the category < 60ml/min . 20 % has fall 
down from >90 and 60 to 90 eGFR to < 60 ml/min  eGFR  following ART 
therapy . So, Overall prevalence of  renal dysfunction is 20%  after ART.  
This indicates that ART use has impact on renal function which can be 
predicted by decline in eGFR.  Percentage and mean decline in eGFR  is 
compared to other trials .  
                       
 
 
 
 
Distribution of cases according to urine albumin : 
             In the present study albuminuria was noted in 47% . Among these 
36 % had insignificant albuminuria , 2+ in 8% and 3+ in 3 % albuminuria  . 
STUDY  PREVALENCE OF 
RENAL DYSDUNCTION 
Msango et.al , Tanzania  25% 
 Chukwuonye et.al
[75] 
50% 
Kenya  and Uganga Trial
[76] 
23% 
DART trial  7% 
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            The incidence of albuminuria in the present  study was comparable to 
that reported with various other studies  
Distribution of cases according to USG – KUB: 
                In the present study 15 % of patients have abnormal sized kidney 
,and 85% have normal size kidneys . 
               According to the study by De Fiori et al., Renomegaly was present 
in 20% of  patients . The  present  study , in contrary  to the  above 
mentioned study has not proven the cases of HIVAN ( though signs and 
symtoms were present ) , because renal biopsy was not done .  
Distribution of cases according to type  of ART regimen : 
               In  the  present study , majority of patients  70% were in Tenofovir  
based  Regimen which included  28% in TLN  and  42% in TLE . 
               Rest of  the  30%  were  in  Zidovudine  based  regimen  which 
includes 22% in ZLN and 8% in ZLE.  Msango et al . , Tanzania study also 
shows the use of  Tenofovir as the first line regimen in HIV outpatients 
group as recommended by WHO  ,though it has nephrotoxic potential . 
 
 
 
 
cxix 
 
Relationship  between ART regimen and  eGFR  at  the end  of  study : 
 
              In the  present study ,Tenofovir based regimen ( Total no.70)  
contributed to most of the moderate to severe decline in eGFR  with 64 % of 
patients  are  under < 90 ml/min , with 38% in < 60 ml/min category . These 
results are comparable to other studies.  
                In the DART  trial the incidence of grade 3 or 4 decreased eGFR 
was 1.7%  for participants on TDF . These changes occurred in a median of 
14 weeks after starting ART 
                  In Western studies, incidence ranged from 1.3% changes in 
creatinine clearance and serum creatinine elevations in ART-experienced 
patients after starting TDF [55], to a cumulative incidence rate of a 
confirmed GFR <70 ml/min of 1.18 per year of TDF use (95% CI: 1.12; 
1.25) in patients with normal baseline renal function (eGFR _90 ml/min) 
                   In a study in Senegal more patients on TDF moved from mild 
(60-90 ml/min/1.73 m2) to moderate  renal impairment (30 - 60 ml/min/1.73 
m2) after a year, compared to patients not on TDF with a  rate ratio of 
transition from mild to moderate  renal impairment of 2.74 in patients 
receiving TDF. 
               In a Copenhagem study by Lene Ryom et al. with total 22,603 
patients . Tenofovir , Ritonavir boosted atazanavir and ritonavir boosted 
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Lopinavir were independent predictors of confirmed eGFR <70ml/min 
indicated chronic renal impairment in HIV positive patients
[77]
  .  
Distribution of cases according to CD4 count and its correlation eGFR 
at the end of study  : 
                In this study , CD4 count at the end of study which is less than 200 
were noted in 24 % of patients .Of which 2 patients had < 100 and 21 
patients had 100 to 200 CD4 counts. Majority of patients with decline in 
CD4 count <200 are in less than 60 eGFR category 
               DART Trial, Longo Ab et al. and other studies  have shown that 
CD4 counts of <200 cells/μL were   predictive of impaired renal function 
and that HIV patients with this severe immune deficiency were more likely 
to develop CKD, particularly if the viral load was >100,000 copies/mL and 
were not on HAART. 
 
Relationship between WHO clinical staging and eGFR : 
                 In this present study , majority of  HIV patients were in WHO 
clinical stage T1 (67%) , and 7 % in T2 , 12% in T3 and and 14 % in T4. 
                  In the category of < 60 ml/min eGFR ,  71 % of T4 and only 36 
% of T1 patients was present, though the frequency of cases was more in T 1 
cxxi 
 
stage . This indicates  that  as the stage of the disease increases ,there is mild 
to moderate reduction in eGFR can occur.  
          However in DART Trial 56% in WHO  T3 and 23% WHO T 4. From 
literature review it was assumed that ,most of the patients with renal 
dysfunction would be in Stage 4 with AIDS defining illness. 
Relationship between Opportunistic infections and e GFR : 
          In the present  study ,there was no correlation between opportunistic 
infections and eGFR at  the end of study . 
          Among our study population apart from Tenofovir based regimen,  
female sex , higher age group , high creatinine value , microalbuminuria , 
CD4 count less than 200 cells /mm
3   
and WHO clinical stage 2 or above are 
the important predictors of  renal dysfunction ,and they were having high 
likelihood of low eGFR at initiation of HAART. 
 
  
 
 
 
cxxii 
 
SUMMARY 
      This study was undertaken to describe the influence of ART 
drugs on e GFR. The  study was conducted in Coimbatore medical college 
with a study population of 100 patients. 
1. The mean age of presentation in our study population was 40.08. There is 
significant correlation between age and eGFR.  
2. In our study 56 % are females, under age group 31- 35. The difference of 
average in eGFR between male and female is not statistically significant. 
3. Mean weight is 48.45 Kg. No significant correlation between weight and 
decline in eGFR. 
4.  Mean Creatinine is 1.028. There is significant P value between Creatinine 
and eGFR. Average levels of Creatinine is significantly  higher (1.26)  for 
<60 eGFR category 
5.  Mean eGFR is 69.28. 20 % of patients with normal baseline  eGFR falls 
into severe decline in eGFR  at the end of study after with ART initiation 
6.  70%  ( 70 patients ) of  patients  fall  under  Tenofovir  based  regimen. Of 
which 64 % patients  falls in eGFR <90 ml/min and in particular  38% falls 
under eGFR < 60 ml/min which indicates moderate to severe renal 
dysfunction.    
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7. Tenofovir based regimen is responsible for most of the decline in renal 
function with 38%  in <60 eGFR category in contrast to only 4% of patients   
in Zidovudine based regimen comes  under < 60ml/min. 
8. In our study 47% had albuminuria . Among them , 26 % have significant 
albuminuria ( 2+, 3+) and all patients had significant decline in eGFR of  
             < 60 .There is a significant P value between Urine albumin and  eGFR . 
9. 15% study population had abnormal kidney size and altered echoes in USG 
KUB and all patients were in eGFR < 60 category .  
10. The patients with CD 4 count less than 200 had  more fall in GFR compared 
to other people with increased CD4 values. 
11. Most of the patients in our study group falls under WHO Stage 1.  As stage 
of  the  disease  increases,  decline  in  eGFR  also  increases. In stage T 4 , 
71% were in < 60 eGFR category. 
12. There is no correlation  between opportunistic infection and decline in GFR. 
This  present  study  indicates  that  associated opportunistic infections does 
not  influence  the  decline  in  renal  function . As the duration of study and 
sample size is less, when compared to other studies , OI”s influence on renal 
function along with nephrotoxic Antiretroviral drugs cannot be studies 
exactly.  
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LIMITATIONS OF THE STUDY 
             Our study is limited , because comparisons are based on 
uncalibrated  creatinine  measurements used for clinical management , and 
other  renal parameters like 24 hour urine protein and renal biopsy was not 
done , making it impossible to distinguish between kidney disease of 
different origin or look into systematically for tubular impairment. 
              Furthermore , eGFR was not directly measured but was estimated 
using  the  Cockcroft – Gault formula, and neither this formula  nor  any 
other formula has been validated in HIV infected patients. However , 
creatinine based GFR estimation is  preferred better  to serum creatinine 
alone , which have a much lower sensitivity  for detecting renal impairment .  
          CG formula is better than MDRD formula ,because  MDRD formula 
does not contain an explicit factor for weight .In resource limited setting like 
ours  , where patients have severe HIV disease , this has the considerable 
disadvantage of ignoring substantial weight gain after ART initiation , with 
increases in muscle mass likely to be responsible for at least some of the 
increase in serum creatinine . 
                   The study was based  at a single academic center and the sample 
size was small when compared to incidence of HIV cases, and our 
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experience may differ from other parts of the world where HIV disease is 
pandemic.  Further studies with large sample size are  required in India  to 
evaluate and posulate the other  predictors of renal dysfunction  along with 
eGFR in HIV patients and the influence of different Antiretroviral drugs for 
decline in renal function . 
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CONCLUSION 
                    This  study  signifies  that  Tenofovir  based  regimen  is  the  
basis for most  of  the  decline  in  renal function in patients on ART.  Renal  
dysfunction is highly prevalent in the study population . This highlights the 
critical and underappreciated  need to monitor renal function in HIV positive 
patients attending ART clinic at CMCH , particularly in this era where 
Tenofovir is being used in  first  line ART regimen in majority of patients  as 
recommended by WHO.  
             So frequent screening of  renal function at regular intervals  is  
mandatory  in  Tenofovir  based  regimen when compared to other regimens   
to  avoid  the further  complications  in  a  HIV patient , who  is  already  
suffering   a incurable dreadful  disease .  
            We also recommend assessment of renal function of HIV infected 
patients prior to initiation of HAART to guide the choice and dosing of 
Antiretroviral drugs.  
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PROFORMA 
Serial No : 
Patient information    
Name :                                                  IP No :                                   Income :                                                 
Age ;                           Sex :                 ART No:                              Address: 
Occupation : 
Diagnosis : 
Symptoms  
Fever                         : Yes/No                                   Dysnea             : Yes/No  
Vomittint                  : Yes/No                                    Palpitation     : Yes /No 
Diarrheoa                  : Yes /No                                  Cough               : Yes/No 
Pedal Edema             : Yes/No                                   Syncope          : Yes /No 
Facial puffiness         : Yes/No                                   Weight loss    : Yes / No 
Decreases urine output : Yes/No                             Miscellaneous   :  Yes /No  
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Past History :  
Diabetes                     :  
Hypertension             : 
Past drug History or any ART intake : 
Chronic renal failure   : 
Associated illness        : 
General physical examination  
Pulse  :                   Pallor :                  Emaciation :                  Pedal edema : 
BP      :                Icterus :                Oral thrush :                   Facial puffiness: 
RR      :                 Cyanosis :               Clubbing :                 
Lymphadenopathy: 
Temp  :                  Weight (KG): 
CVS    : 
RS      : 
PA      :                            CNS   : 
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INVESTIGATIONS & DATA s collected : 
1) Baseline Urea  ( Before ART )                : 
2) Baseline  Creatinine  ( Before ART )      : 
3) At the end of 10th month  Urea                :  
4) At the end of 10th month Creatinine        : 
5) Urine  Albumin                                        : 
6) Ultrasound  KUB ( Kidney , Bladder, Ureter )     :   Renomegaly  
                                                                                       present /absent  
7) Baseline CD 4 count             : 
8) At the end CD 4 count          : 
9)  Type of regimen started           :    TLN/ TLE / ZLN  /ZLE 
10)  Stage of the disease               : 
 11) Associated opportunistic infection (OI ‘s ) 
 Throughout the course of study : 
 12) Miscellaneous : 
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MASTER CHART 
SL.NO NAME AGE  SEX 
WT 
in KG 
UREA 
( B ) 
CREAT 
(B) 
eGFR 
( B) 
UREA 
( E) 
CREAT 
( E) 
eGFR 
( E ) 
URINE 
ALB 
USG 
KUB 
  
CD4 ( B ) 
CD4 
( E )     OI'S STAGE 
REGI
MEN 
1 Puspha 44 F 45 25 0.7 72 22 1 51 Trace Nor Q R No T3 A 
2 Nagamani 34 F 50 28 1 62.5 40 1.2 52.1 Nil Nor Q R  PT T1 B 
3 Kavitha 34 F 40 25 1 50 20 0.8 62.5 Nil Nor P P PT T2 B 
4 Raman 33 M 46 22 0.7 97.6 18 1.2 56.9 Trace Nor P R PT T3 B 
5 Murugeshan 44 M 55 24 1.1 66.6 26 1.2 61.1 Trace Nor R R No T1 C 
6 Duraisamy 56 M 50 23 1.4 41.6 30 1.8 32.4 3+ R* R R No T1 A 
7 Sokkalingam 51 M 54 25 0.9 74.2 20 0.9 74.2 Trace Nor R R No T1 C 
8 Sanjay 32 M 46 24 0.9 98.5 29 1.2 57.5 1+ Nor P R PT T4 D 
9 Hussain 35 M 56 33 0.9 90.7 25 0.7 116.6 Nil Nor R Q Acute GE T1 C 
10 Sarojini 36 F 54 24 0.5 132.6 26 1.2 55.5 Trace Nor R R No T1 B 
11 Mallika 40 F 58 41 1.1 62.2 28 1.2 57 1+ Nor R R No T1 A 
12 Arputhamani 31 M 50 29 0.8 94.6 28 1.1 94.6 1+ Nor R R No T1 C 
13 Marimuthu 44 M 44 36 0.9 65.2 33 0.9 58.6 Nil Nor Q R Tb Meningitis T4 B 
14 Rajeswari 49 F 55 30 1 55.8 28 1.2 50.7 Trace Nor R R No T3 B 
15 Meena 39 F 42 40 0.7 71.5 27 0.5 100.2 Nil Nor P Q No T1 C 
16 Raja 40 M 56 28 0.8 97.2 30 1 97.2 Nil Nor R R HZ T1 C 
17 Murugesan 49 M 51 28 0.9 70.2 44 0.8 80 Nil Nor R R No T1 A 
18 Balanangammal 49 F 49 27 0.7 75.2 28 0.8 65.8 Nil Nor R R No T1 B 
19 Rangananthan 43 M 45 37 0.9 67.3 27 1.2 50.5 Trace Nor Q R Tb Pleural effusion T4 D 
20 Kamatchi 33 F 38 20 0.9 43.3 28 0.6 65 Nil Nor Q Q PT T3 D 
21 Ramasamy 27 M 27 35 0.8 98 35 1.2 60.3 Nil Nor R R No T1 A 
22 Jancy 33 F 33 36 0.7 77.5 23 1.2 45.2 Trace Nor P R HZ T1 A 
23 Ramalingam 56 M 48 33 1.2 46.6 35 0.6 93.3 Nil Nor Q Q No T1 A 
24 Nanjammal 70 F 46 24 1 38 28 1.2 31.6 2+ R* Q R No T1 A 
25 Krishnaveni 40 F 47 29 0.8 69.3 16 0.5 110.9 Nil Nor Q R Acute GE T1 C 
26 Kalaivani 34 F 50 28 1.1 56.8 30 1.2 52.14 Nil Nor R R No T1 C 
27 Manikandan 28 M 54 26 0.6 140 28 1.1 76.3 Nil Nor R Q No T1 B 
28 Kalikutty 35 M 55 30 1 80.2 32 1.4 57.2 Trace Nor R Q Acute GE T3 B 
29 Poongodi 30 F 40 24 0.8 64.9 25 1.4 37 2+ R* P Q CNS Toxoplasmosis T4 A 
30 Rukmani 42 F 47 15 1 54.3 19 0.6 90.6 Nil Nor Q Q No T2 A 
31 Baby 40 F 49 24 0.9 64.2 19 0.6 64.2 Nil Nor Q R No T1 C 
32 Kumar 35 M 56 32 0.9 90.7 32 0.9 102.8 Nil Nor Q R No T2 C 
33 Sivakolundu 42 M 55 20 0.6 124.7 25 0.8 106.4 Nil Nor Q R Tb lymphadenitis T1 C 
34 Lakshmi 40 F 48 35 1 56.6 33 0.7 56.6 1+ R* Q Q No T1 A 
35 Harisudhan 20 M 35 23 0.6 97.2 37 0.8 72.9 Nil Nor Q Q No T1 C 
36 Dharmaraj 60 M 51 30 0.4 141 25 0.5 80.9 Nil Nor R R PT T1 B 
37 Subramaniyan 57 M 54 40 0.4 155.6 30 0.7 51.8 Nil Nor R R No T1 B 
38 Palaniyammal 35 M 53 28 1 77.2 28 1.2 77.2 Trace Nor R R No T1 A 
39 Saraswathy 38 F 53 19 0.8 71.9 21 1 57.5 NIl Nor R R No T1 B 
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40 Shanthamani 45 F 45 34 0.8 63 40 1.2 42.05 1+ R* P Q 
OC+ HIV 
myelopathy T3 B 
41 Moorthy 27 M 56 26 1.1 79.8 24 0.8 109.8 Nil Nor R R PT T1 C 
42 Bhagawatheswari 30 F 46 28 0.7 85.3 27 0.8 99.5 Nil Nor P R Tb lymphadenitis T3 C 
43 Subhashini 30 F 48 27 0.7 89 24 0.5 124.6 Nil Nor R R No T1 A 
44 Krishnasamy 53 M 58 29 1.2 58 31 0.8 87.6 Nil Nor R R No T1 C 
45 Sagunthan 50 M 55 29 0.7 98.2 20 0.8 85.9 Nil Nor R R HZ T1 A 
46 Dharmaraj 45 M 50 20 0.7 94.2 18 0.8 82.4 Nil Nor R R Tb spine T4 C 
47 Nirmala 48 F 46 27 0.9 55.5 23 0.6 83.2 Nil Nor Q R No T1 C 
48 Manikandan.K 43 M 57 21 1 76.7 22 1.4 54.8 1+ R* R R Tb Pleural effusion T4 B 
49 Shanmugam 45 M 42 35 0.8 69.2 29 1.1 50.3 Trace Nor P R No T1 A 
50 Vanitha 31 F 43 23 0.7 79.1 24 1 55.3 Trace Nor P R HZ T1 A 
51 Kavitha 20 F 39 19 0.7 78.9 30 1.2 46.04 2+ R* R R No T1 B 
52 Vairam 50 F 54 23 0.6 95.6 25 1.2 47.8 2+ R* R Q No T1 B 
53 Sivagamisundari 81 F 44 23 0.9 34.5 23 0.6 25.5 Trace Nor P Q No T4 B 
54 Papa 44 F 52 23 0.5 117 25 0.7 98.2 Nil Nor R R Acute GE T1 B 
55 Jayalakshmi 48 F 57 28 0.6 103 24 0.5 88.4 Nil Nor R Q No T1 B 
56 Unnamalai 35 F 40 27 0.7 70.8 31 1.1 99.16 Nil Nor P R OC T2 B 
57 Sundharambhal 40 F 40 24 1 47.2 26 1.2 39.5 Trace Nor R R No T1 A 
58 Saroja 40 F 40 24 1 49.5 31 1.4 35.4 Trace Nor Q R SEBORRHEA T1 A 
59 Murugeshan 27 M 50 25 1 78.4 28 0.8 98 Nil Nor R R Tb Pleural Effusion T1 D 
60 Dhanapal 48 M 55 29 0.7 103.7 28 1.2 60.4 Trace Nor Q R PPE T1 B 
61 Mailathal 60 F 47 24 1 44.3 29 1.2 36.9 1+ R* R R No T1 B 
62 Sundaram 60 M 49 28 1.2 45.3 32 1.4 60.4 1+ Nor Q Q PCP T4 B 
63 Babu 50 M 54 40 0.7 96.4 40 1.2 56.2 Trace Nor Q R No T1 B 
64 Mariappan 45 M 43 24 0.4 141 31 1.3 37.8 2+ R* P P PT+PCP T4 D 
65 Vinothini 21 F 46 24 0.6 107.7 27 0.5 129 Nil Nor R R OC T2 C 
66 Sampathkumar 43 M 56 24 0.8 94 32 1 75.4 Nil Nor R R PT T1 B 
67 Vasanthi 30 F 54 27 0.9 77.9 33 1.3 77.9 Nil Nor R R HZ T1 A 
68 Baskaran 32 M 54 31 0.8 101.2 32 1.4 67.5 Trace Nor R R No T1 B 
69 Anandhi 40 F 55 24 0.6 108.2 24 0.8 81.1 Nil Nor R R No T1 B 
70 Chithra 26 F 41 27 0.8 68.9 33 1.5 39.4 1+ Nor R R No T1 B 
71 Sathiyarani 33 F 44 27 0.8 69.4 34 1.3 37 1+ R* R R No T1 B 
72 Eswari 39 F 52 20 0.8 77 24 0.9 69 Trace Nor R R Acute GE T1 B 
73 Radhamani 35 F 54 25 0.9 74.3 40 1.2 55.7 Trace Nor Q R PPE T1 B 
74 Palanisamy 34 M 52 25 0.9 85 28 0.6 127.5 Nil Nor Q R SEBORRHEA T4 D 
75 Saravanan 30 M 56 31 1.5 57 28 0.6 143 Nil Nor R R PT T1 C 
76 Shanmugapandi 35 M 49 26 0.8 89.3 31 1.2 79 Nil Nor Q R No T2 A 
77 Sutha 30 F 52 22 0.9 75 32 1.4 56.2 Nil Nor Q Q HZ T2 A 
78 Manickam 41 M 54 32 0.9 82.5 34 1.3 83 Nil Nor Q R PPE T1 A 
79 Rajathi 56 F 54 24 0.9 70 33 1.6 43 2+ R* R R Acute GE T1 A 
80 Meenakshi 44 F 46 23 0.9 57.9 27 0.6 87 Nil Nor Q R No T1 A 
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81 Manimegalai 28 F 45 25 0.8 74.3 28 0.8 74 Nil Nor R R No T1 B 
82 Venkatakrishnan 50 M 53 21 0.5 132 26 1 66 Nil Nor R R Tb meningitis T4 B 
83 Bharani 20 F 42 20 0.7 107 24 0.5 115 Nil Nor R R No T1 A 
84 Santhamani 40 F 56 29 1 67 24 0.8 84 Nil Nor R R PT T3 D 
85 Saravanan 35 M 50 30 0.5 145 31 1.2 73 Nil Nor Q Q PT T3 D 
86 Vasanthi 53 F 49 27 1.2 42 23 0.7 72 Trace Nor R R No T1 C 
87 Sumathi 28 F 45 26 0.7 85 29 0.8 119 Nil Nor Q R No T1 C 
88 Sethulakshmi 48 F 42 30 0.8 57 32 1.3 51 Trace Nor P R PT+PCP T3 B 
89 Mani 52 M 46 28 0.8 70.2 28 0.9 63 Trace Nor Q R PT T3 A 
90 Ganesan 35 M 42 21 0.8 76.5 27 1.7 36 1+ Nor Q R No T1 B 
91 Jayanthi 29 F 43 26 0.7 80.4 32 1.4 40 1+ Nor R R PT+PCP T1 B 
92 Vanitha 35 F 47 25 1.2 48.5 27 0.7 84 Nil Nor Q R No T1 A 
93 Kasthuri 33 F 49 26 0.7 90.2 25 0.6 105 Nil Nor R R HZ T1 C 
94 Senbagavalli 25 F 40 31 1 54.3 34 1.6 34 2+ R* P Q PT+PCP T3 B 
95 Shanmugam 37 M 55 27 0.8 98.3 31 1.2 66 Nil Nor R R PT+OC T1 A 
96 Sarathamani 55 F 52 20 0.9 102 28 1 62 Nil Nor R R No T1 B 
97 Krishna Roa 45 M 46 24 0.9 101 20 0.9 71 Trace Nor R R No T1 B 
98 Mariammal 24 F 39 26 0.8 67 32 1.5 35.6 2+ Nor P Q CMV RETINITIS T4 B 
99 Petchiammal 55 F 43 22 0.7 62 36 1.8 24 3+ R* P Q 
CNS 
TOXOPLASMOSIS T4 B 
100 Kumari 33 F 47 20 1 60 38 1.8 33 3+ R* P Q HIV Myelopathy T4 B 
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MASTER CHART 
B          :      Baseline value 
E          :      value at the end of 10 months 
M         :    Male 
F          :  Female 
P          :  CD4 count <100  
Q          :  CD4 count 100- 200 
R          :   CD4 count > 200 
R*         :   Renomegaly/ Contracted kidney  
eGFR   :     Estimated glomerular Filtration Rate 
ALB     :  Albumin 
USG KUB  :  Ultrasound kidney Bladder Ureter 
OI’s           :  Opportunistic Infections 
PT         :  Pulmonary tuberculosis 
GE          :  Gastroenteritis 
OC         :   Oral /Oesophageal candidiasis 
PPE        :  Pruritic Papular eruptions 
PCP        :  Pneumocystitis carnii pneumonia 
A          :    Regimen  TLN ( tenofovir,Lamivudine , Nevirapine) 
B          :    Regimen TLE   ( Tenofovir, Lamivudine, Efavirenz) 
C  :   Regimen  ZLN ( Zidovudine, Lamivudine,Nevirapine) 
D          :   Regimen  ZLE  ( Zidovudine , Lamivudine , Efavirenz ) 
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CONSENT  FORM 
Yourself   Mr./Mrs./Ms. ……………………………………  are   
being  asked   to   be  a  participant  in  the  research  study  titled  
 “Estimated  Glomerular Filtration  Rate  As  A  Predictor  Of  Renal  
Dysfunction  Among  Adult  HIV  Patients  On  HAART”   in  CMC  
hospital, Coimbatore , conducted  by  DR.GAYATHRI.,  Post  Graduate  
Student, Department   of  General  Medicine, Coimbatore  Medical  College.  
You  are  eligible  after  looking  into  the  inclusion  criteria  .You  can  ask  
any  question  which  you  may  have  before  agreeing  to  participate.   
Research  Being  Done : 
Estimated  Glomerular  Filtration  Rate  As  A  Predictor  Of  Renal  
Dysfunction  Among   HIV  Patients  On  HAART . 
Purpose  of  Research : 
1. To study the Renal Changes  in Adult HIV Patients following  first line 
HAART initiation using eGFR. 
2. To study the Renal changes and decline in  eGFR with  respect to the different 
HAART regimens after the HAART initiation by using Cockcroft – Gault 
formula 
Decline  from  Participation : 
You  have  the  option  to  decline  from  participation  in  the  study    
existing  protocol  for  your  condition. 
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Privacy  and  Confidentiality : 
Privacy  of  individuals  will  be  respected  and  any  information  
about  you  or  provided  by  you  during  the  study  will  be  kept  strictly  
confidential. 
Authorization  to  publish  Results : 
Results  of  the  study  may  be  published  for  scientific  purposes   
and/or  presented  to scientific  groups,  however  you  will  not  be  
identified. 
Statement  of  Consent : 
I   volunteer   and  consent  to  participate   in   this  study.  I  have  
read  the  consent   or   it   has   been   read   to  me  . The   study   has   been  
fully  explained  to   me,  and   I  may  questions   at  any  time. 
 
……………………………….                                          …………………… 
Signature/Left  thumb  impression                                              Date  
          ( volunteer ) 
 
………………………………                                           …………………… 
      Signature   of   witness                                                          Date 
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xg;g[jy; gotk; 
 
bgah;  :        taJ : 
ghypdk; : 
Kfthp : 
 
 muR nfhit kUj;Jtf; fy;Y}hapy; bghJ kUj;Jtj; Jiwapy; gl;l 
gapYk; khztp mth;fs; nkw;bfhs;Sk; “vr;/I/tp nehahspfspy; 
v/Mh;/o khj;jpiu cl;bfhs;gth;fspy; rpWePuf ghjpg;gpid 
Kd;Tl;ona mwpa cjt[k; $p/vg;/Mh;” Fwpj;j Ma;tpy; bra;Kiw 
kw;Wk; midj;J tptu';fisa[k; nfl;Lf; bfhz;L vdJ re;njf';fis 
bjspt[g;gLj;jpf; bfhz;nld; vd;gij bjhptpj;Jf;bfhs;fpnwd;/ 
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;. Ra rpe;jida[lDk; fye;J bfhs;s 
rk;kjpf;fpnwd;/ 
 ,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; ghJfhf;fg;gLtJld; ,jd; 
Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; 
bfhs;fpnwd;/  ve;j neuj;jpYk; ,e;j Ma;tpypUe;J ehd; tpyfpf; bfhs;s 
vdf;F chpik cz;L vd;gija[k; mwpntd;/ 
 
,lk; :       ifbahg;gk; - nuif 
ehs;   : 
